

No. 360-Induced Abortion: Surgical Abortion and Second Trimester Medical Methods

This guideline has been prepared by the Surgical Abortion Working Group, reviewed by the Guideline Management and Oversight Committee, and approved by the Board of the Society of Obstetricians and Gynaecologists of Canada.

Dustin Costescu, MD, Hamilton, ON (Co-chair)
Édith Guilbert, MD, Québec City, QC (Co-chair)

Surgical Abortion Working Group: Dustin Costescu, MD, Hamilton, ON (Co-chair); Édith Guilbert, MD, Québec City, QC (Co-chair); Jeanne Bernardin, MD, Moncton, NB; Amanda Black, MD, Ottawa, ON; Sheila Dunn, MD, Toronto, ON; Megan Gomes, MD, Ottawa, ON; Brian Fitzsimmons, MD, Vancouver, BC; Lola McNamara, RN, Gatineau, QC; Wendy V Norman, MD, Vancouver, BC; Regina Renner, MD, Vancouver, BC; Konia Trouton, MD, MPH, Victoria, BC and Calgary, AB; Marie-Soleil Wagner, MD, Montréal, QC.

Disclosure statements have been received from all authors.

Key Words: Induced abortion, aspiration curettage, dilation and evacuation, second-trimester induction, family planning

Abstract

Objective: This guideline reviews evidence relating to the provision of surgical induced abortion (IA) and second trimester medical abortion, including pre- and post-procedural care.

Intended Users: Gynaecologists, family physicians, nurses, midwives, residents, and other health care providers who currently or intend to provide and/or teach IAs.

Target Population: Women with an unintended or abnormal first or second trimester pregnancy.

Evidence: PubMed, Medline, and the Cochrane Database were searched using the key words: first-trimester surgical abortion, second-trimester surgical abortion, second-trimester medical abortion, dilation and evacuation, induction abortion, feticide, cervical preparation, cervical dilation, abortion complications. Results were restricted to English or French systematic reviews, randomized controlled trials, clinical trials, and observational studies published from 1979 to July 2017. National and international clinical practice guidelines were consulted for review. Grey literature was not searched.

Values: The quality of evidence in this document was rated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology framework. The summary of findings is available upon request.

Benefits, Harms, and/or Costs: IA is safe and effective. The benefits of IA outweigh the potential harms or costs. No new direct harms or costs identified with these guidelines.

J Obstet Gynaecol Can 2018;40(6):750–783

<https://doi.org/10.1016/j.jogc.2017.12.010>

© 2018 Society of Obstetricians and Gynaecologists of Canada. Published by Elsevier Inc. All rights reserved.

This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the publisher.

Patients have the right and responsibility to make informed decisions about their care in partnership with their health care providers. In order to facilitate informed choice patients should be provided with information and support that is evidence based, culturally appropriate, and tailored to their needs. The values, beliefs, and individual needs of each patient and their family should be sought, and the final decision about the care and treatment options chosen by the patient should be respected.

SUMMARY STATEMENTS

Periprocedural Care

1. Women seek abortion for many reasons, each of which is valid. Counselling needs may differ for women with an unintended pregnancy than for those with an intended but abnormal pregnancy.
2. Doxycycline, metronidazole, and beta-lactams are each suitable to reduce the risk of post-abortal infection (Level of evidence: High).
3. Moderate sedation combined with a paracervical block provides improved intraoperative pain control compared with local anaesthesia alone (Level of evidence: High).
4. Feticide prior to second trimester surgical abortion is associated with more side effects and a higher complication rate without reduction in operating time (Level of evidence: Low).
5. More evidence is required to determine if feticide prior to second trimester medical abortion confers benefit (Level of evidence: Very low).

Method Selection and Technique

6. Intracervical vasopressin may reduce blood loss in second trimester surgical abortion (Level of evidence: Low).
7. For early second trimester surgical abortion, use of buccal/vaginal misoprostol 400 µg 3–4 hours before dilation and evacuation:
 - a. may not achieve as much dilation as osmotic dilators alone (Level of evidence: Moderate).
 - b. results in similar complication rates as for osmotic dilators, but does increase side effects (Level of evidence: Medium).
 - c. reduces ease of procedure compared with use of osmotic dilator (Level of evidence: High).
8. More research is required to state whether use of mifepristone confers benefit for cervical dilation prior to early second trimester surgical abortion (Level of evidence: Very low).
9. For late second trimester surgical abortion, use of buccal misoprostol 400 µg 3–4 hours plus laminaria/synthetic osmotic dilators before D&E:

ABBREVIATIONS

CHC	combined hormonal contraception
CI	confidence interval
COC	combined oral contraceptives
CS	Caesarean section
D&C	dilation and curettage
D&E	dilation and evacuation
DMPA	depo-medroxyprogesterone acetate
EC	emergency contraception
EVA	electric vacuum aspiration
EP	ectopic pregnancy
FU	follow-up
GA	gestational age
GAn	general anaesthesia
GRADE	Grading of Recommendations, Assessment, Development, and Evaluation
GS	gestational sac
GTN	gestational trophoblastic neoplasia
hCG	human chorionic gonadotropin
IA	induced abortion
IUP	intrauterine pregnancy
DIC	disseminated intravascular coagulation
IM	intramuscular
IV	intravenous(ly)
KCl	potassium chloride
IUCD	intrauterine contraceptive device

LBW	low birth weight
MA	medical abortion
MIFE	mifepristone
MISO	misoprostol
MVA	manual vacuum aspiration
NO donors	nitric oxide donors
NSAID	non-steroidal anti-inflammatory drug
OD	synthetic osmotic dilators
OR	odds ratio
PCA	patient-controlled analgesia
PCB	paracervical block
PGF _{2α}	prostaglandin F _{2α}
PGE ₁	prostaglandin E ₁
PGE ₂	prostaglandin E ₂
POC	products of conception
PP	placenta previa
PTB	preterm birth
PUL	pregnancy of unknown location
RCT	randomized controlled trial
RR	risk ratio
SA	surgical abortion
SGA	small for gestational age
SOGC	Society of Obstetricians and Gynaecologists of Canada
UP	uterine perforation

- achieves significantly more dilation than osmotic dilators alone, without influencing procedure time (Level of evidence: Moderate).
 - does not decrease severe complications (Level of evidence: Moderate), but may produce prostaglandin side effects (Level of evidence: Low).
10. For late second trimester surgical abortion, use of mifepristone overnight with osmotic dilators and/or buccal/sublingual/vaginal misoprostol 400 µg 3–4 hours before D&E facilitates cervical preparation and decreases procedure time (Level of evidence: Low).
 11. For second trimester medical abortion:
 - use of mifepristone 24–48 hours prior to induction reduces time to expulsion without added side effects (Level of evidence: High).
 - mechanical dilation with intracervical catheters prior to induction rarely confers benefit (Level of evidence: Low).
 - laminaria/synthetic osmotic dilators prior to induction do not confer any benefit and may increase both pain and time to expulsion (Level of evidence: Moderate).
 12. Immediate placement of intrauterine contraception reduces repeat abortion and unintended pregnancy compared with other methods (Level of evidence: Moderate).

Post-Abortion Care

13. An abundant amount of evidence provides reassurance concerning future reproductive outcomes following induced abortion (Level of evidence: Low).
14. Sharp curettage during induced abortion is associated with the development of uterine adhesions, risk of miscarriage, placenta previa, and subfertility (Level of evidence: Low).

RECOMMENDATIONS

Periprocedural Care

1. A preprocedural assessment should take place prior to induced abortion to identify somatic and mental health conditions associated with an elevated risk of complications and therefore warrant an in-hospital procedure (Strong recommendation. Level of evidence: Very low).
2. Women should be given an opportunity to explore the circumstances around their decision to undergo induced abortion and be offered counselling as deemed necessary (Strong Recommendation. Level of evidence: Low).
3. Ultrasound should be performed prior to induced abortion to confirm gestational age and aid in operative

- planning (Strong recommendation. Level of evidence: Low).
4. Placental localization by ultrasound is recommended before second trimester abortion when placenta previa is suspected, and when there is a history of uterine scar (Strong recommendation. Level of evidence: Very low).
 5. Expert consultation is advised when invasive placenta is suspected, particularly in women with a uterine scar (Strong recommendation. Level of evidence: Very low).
 6. Preoperative antibiotics should be given to all women undergoing surgical abortion (Strong recommendation. Level of evidence: High).
 7. Women at risk or suspected to have a sexually transmitted infection should be screened at the time of abortion. If positive, the woman should receive evidence-based treatment, in addition to any pre-procedural antibiotics received. (Strong recommendation. Level of evidence: Very low).
 8. Women should be offered contraception counselling before abortion, and provided with their chosen method (Strong recommendation. Level of evidence: Low).
 9. Women undergoing first trimester surgical abortion with no contraindications should receive non-steroidal anti-inflammatory medication (Strong recommendation. Level of evidence: High).
 10. Moderate sedation combined with a paracervical block should be offered to women undergoing first or second trimester surgical abortion when available (Strong recommendation. Level of evidence: High).
 11. Feticide may be performed prior to second trimester surgical abortion, following discussion of both medical and psychosocial considerations (Weak recommendation. Level of evidence: Low).
 12. Feticide may be performed prior to second trimester medical abortion, following discussion of both medical and psychosocial considerations (Weak recommendation. Level of evidence: Very low).

Method Selection and Technique

13. Early surgical abortion (<7 weeks) should be performed with routine preoperative and postoperative ultrasound, direct examination of products of conception, and β -human chorionic gonadotropin follow-up when products of conception are not identified (Strong recommendation. Level of evidence: Low).
14. For women who cannot or refuse serial β -human chorionic gonadotropin follow-up following early surgical abortion, the procedure should be delayed until an intrauterine pregnancy can be confirmed (Strong recommendation. Level of evidence: Very low).

15. Cervical preparation is not routinely required prior to first trimester surgical abortion (Strong recommendation. Level of evidence: Moderate).
16. Cervical priming before first trimester surgical abortion may be considered in nulliparous women, and when cervical dilation is expected to be difficult (Weak recommendation. Level of evidence : Very low).
17. The following are recommended cervical preparation regimens (Strong recommendation; Level of evidence: High):
 - a. misoprostol 400 µg vaginally 3 hours pre-procedure; or
 - b. misoprostol 400 µg sublingually, 2–3 hours pre-procedure; or
 - c. laminaria placed intracervically 6–24 hours pre-procedure; or
 - d. synthetic osmotic dilator placed intracervically 3–4 hours pre-procedure; or
 - e. mifepristone 200–400 mg orally, 24–48 hours prior to procedure.
18. Vasopressin 4 units added to a 20-mL paracervical block during second trimester surgical abortion may be used to reduce blood loss (Strong recommendation. Level of evidence: Low).
19. The use of misoprostol for second trimester medical abortion is safe after 1 prior low-transverse Caesarean section. There is insufficient evidence regarding its use in women with 2 or more prior Caesarean sections or a prior classical Caesarean section (Weak recommendation. Level of evidence: Very low).
20. For early second trimester surgical abortion, cervical preparation can be achieved with laminaria/synthetic osmotic dilators alone or misoprostol 400 µg 3–4 hours pre-procedure (Strong recommendation. Level of evidence: Moderate).
21. For early second trimester surgical abortion, mifepristone is not recommended for cervical preparation (Weak recommendation. Level of evidence: Very low).
22. For late second trimester surgical abortion, the addition of misoprostol 400 µg 3–4 hours pre D&E after serial insertions of osmotic dilators is recommended, but is associated with side effects (Strong recommendation. Level of evidence: Moderate).
23. For late second trimester surgical abortion, use of prior-day mifepristone 200 mg orally is recommended, in addition to osmotic dilators and/or misoprostol 400 µg 3–4 hours pre-procedure (Weak recommendation. Level of evidence: Low).
24. For second trimester medical abortion, use of mifepristone 24–48 hours prior to misoprostol induction is recommended (Strong recommendation. Level of evidence: High). The specific timing of mifepristone should be based on provider and patient preference (Weak recommendation. Level of evidence: Moderate).
25. For second trimester medical abortion, use of mechanical dilation or osmotic dilator prior to induction is not recommended (Strong recommendation. Level of evidence: Low). Mechanical dilation may be considered when other cervical priming approaches must be avoided (Weak recommendation. Level of evidence: Low),
26. For second trimester medical abortion, there is insufficient evidence to recommend the use of nitric oxide donors or misoprostol priming prior to induction (Weak recommendation. Level of evidence: Low),
27. In the presence of placenta praevia, intracervical vasopressin, ultrasound guidance, and rapid removal of the placenta are recommended. Expert backup is advised in case of significant bleeding (Strong recommendation. Level of evidence: Very low),
28. Routine gross examination of the uterine contents should be performed immediately after induced abortion (Strong recommendation. Level of evidence: Very low),
29. Histopathological examination of products of conception must be performed when gestational trophoblastic neoplasia or ectopic pregnancy is suspected (Strong recommendation. Level of evidence: Very low).

Post-Abortion Care

30. Every facility where abortions are performed should have written emergency protocols (Strong recommendation. Level of evidence: Very low).
31. Every facility where abortions are performed should engage in regular emergency drills (Strong recommendation. Level of evidence: Very low).
32. If women fail to have a period within 8 weeks following induced abortion and/or complain of continuing symptoms and signs of pregnancy, a new or ongoing pregnancy should be suspected and repeat procedure offered (Strong recommendation. Level of evidence: Very low).
33. Sharp curettage is not recommended as a replacement for vacuum aspiration (Strong recommendation. Level of evidence: Low), nor should routine sharp curettage be performed during induced abortion (Weak recommendation. Level of evidence: Low).
34. Contraception should be started as soon as possible after the abortion (Strong recommendation. Level of evidence: High).
35. Women referred for abortion from a fetal diagnosis clinic should be offered follow-up to review any additional information obtained from the abortion and

provide support (Strong recommendation. Level of evidence: Low).

INTRODUCTION

Definition and Scope

In Canada, approximately 100 000 Induced Abortions (IAs) occur annually.¹ Most IAs are surgical (95%), and over two thirds take place within 13 gestational weeks.¹ First trimester SA is defined as less than 14 weeks from last menstrual period. Second trimester IA is defined as taking place between 14 and 24 weeks. Second trimester SA, most commonly D&E, is performed following cervical preparation and requires specialized training; second trimester MA uses various pharmacological combinations to effect expulsion (vaginal delivery) of the pregnancy, usually in a supervised setting. In Canada, there were 587 terminations over 21 weeks reported in 2015.¹

These guidelines review evidence regarding first trimester SA and second trimester SA and MA. First trimester MA is addressed in another SOGC guideline.² Recognizing that other clinical practice or accreditation standards exists,³ this guideline is intended for providers who wish to review current best practices and evidence. It is also intended for obstetrician/gynaecologists and family physicians who provide abortions, some of whom may not be members of an abortion provider organization.

The quality of evidence in this document was rated using the criteria described in the GRADE methodology framework (Table 1). The interpretation of strong and conditional (weak) recommendations is described in Table 2.

Surgical Abortion Providers

In Canada, most abortion providers are family physicians, followed by gynaecologists.⁴ Physicians and adequately trained midlevel providers (midwives, nurses, and others) may safely provide first trimester IA. Although a 2015 Cochrane review⁵ showed that complication rates were similar, SA failure rate was slightly increased with midlevel providers.⁶⁻¹⁰

PERIPROCEDURAL CARE

Women who are contemplating IA require timely care. A comprehensive review of pre-abortion care is included in the first trimester MA guideline, including a detailed discussion outlining differences in outcomes, risks, and patient preferences regarding medical versus surgical abortion.² In general, MA and SA are equivalent prior to 49 days' GA, and there is a small increased risk of subsequent treatment (aspiration) and bleeding with MA beyond this limit.²

Table 1. Key to GRADE^{1,2}

Strength of the recommendation	Definition
Strong	Highly confident of the balance between desirable and undesirable consequences (ie, desirable consequences outweigh the undesirable consequences, or undesirable consequences outweigh the desirable consequences).
Weak ^a	Less confident of the balance between desirable and undesirable consequences.

Quality level of a body of evidence	Definition
High ++++	We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate +++0	We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low ++00	Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
Very low +000	We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

Examples:
 Strong, moderate|+++0: Strong recommendation, moderate quality of evidence.
 Weak, low|++00: Weak recommendation, low quality of evidence.
^aWeak recommendations should not be misinterpreted as weak evidence or uncertainty of the recommendation.

Medical Assessment

A medical evaluation is required to identify women at elevated risk of an adverse event and those who may benefit from a hospital-based procedure.¹¹ A minimal physical examination consists of height, weight, vital signs, and pelvic exam. Further examination is directed by history. Rh status should be determined in all women.

Lack of vaginal parity and prior cervical surgery may lead to poor cervical dilation.¹² Obese women experience increased operative times, with no increase in complications.^{13,14} Women with uncontrolled medical conditions may require specialist consultation or, rarely, admission.¹¹ Women with American Society of Anesthesiologists status of 3 or greater should undergo anaesthesia consultation and may require anaesthesia support during IA.^{3,15,16} Laboratory investigations should be directed by history.¹⁷ A history of CS is associated with a higher rate of SA complications (OR 1.9, 95% CI 1.1-3.4).¹⁸ The presence of placenta previa (PP), low anterior placenta with a history of CS, or bleeding diathesis increases the risk of hemorrhage.^{12,18}

Table 2. Judgement and interpretation of strong and conditional recommendations^{1,2}

Judgement/interpretation	Strong recommendation, “We recommend...”	Conditional (weak) recommendation, “We suggest...”
Judgement by guideline panel	It is clear to the panel that the net desirable consequences of a strategy outweighed the consequences of the alternative strategy.	It is less clear to the panel whether the net desirable consequences of a strategy outweighed the alternative strategy.
Implications for patients	Most individuals in this situation would want the recommended course of action, and only a small proportion would not.	Most individuals in this situation would want the suggested course of action, but many would not.
Implications for clinicians	Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator.	Clinicians should recognize that different choices will be appropriate for each individual and that clinicians must help each individual to arrive at a management decision consistent with his or her values and preferences.
Implications for policy makers	The recommendation can be adopted as policy in most situations.	Policy making will require substantial debate and involvement of various stakeholders.

If sedation is provided, nil per os status should be reviewed, and cardiorespiratory and airway examination performed.^{15,16} The American Society of Anesthesiologists recommends fasting for 2 hours for clear fluids and 6 hours for solids prior to moderate sedation.^{15,16} Two retrospective studies, 1 involving over 47 000 cases, found no increase in complications related to low-dose sedation protocols with midazolam and fentanyl in women who had a light meal before undergoing SA up to 18 weeks of gestation.^{19,20}

Women may have discontinued certain medications upon learning of the pregnancy, in particular mood-stabilizers. Reviewing mental health conditions and medication histories may identify women who would benefit from additional anxiolysis or guidance on restarting their medications.

As discussed in the MA guideline,² women should be given an opportunity to discuss the circumstances surrounding the abortion decision. Some women present for abortion owing to a fetal diagnosis or change in circumstance in the setting of a wanted pregnancy. Common practice suggests that these women (and the man involved in the pregnancy) benefit from counselling; however, we could not identify studies that quantified this benefit.

Summary Statement

1. Women seek abortion for many reasons, each of which is valid. Counselling needs may differ for women with an unintended pregnancy than for those with an intended but abnormal pregnancy.

Recommendations

1. A preprocedural assessment should take place prior to induced abortion to identify somatic and mental health conditions associated with an elevated risk of

complications and therefore warrant an in-hospital procedure (Strong recommendation. Level of evidence: Very low).

2. Women should be given an opportunity to explore the circumstances around their decision to undergo induced abortion and be offered counselling as deemed necessary (Strong Recommendation. Level of evidence: Low).

Ultrasound Scanning Including Localization of Placenta and Management of Abnormal Placentation

Routine ultrasound prior to IA is recommended, as determination of GA is critical.²¹ In second trimester SA, intraoperative ultrasound has been shown to decrease complications including uterine perforation (UP).²²

In the second trimester, ultrasound is important to determine placental localization.²³ If the placenta is anterior and low lying or previa, the risk of hemorrhage can be substantial.²⁴ In the presence of a uterine scar, further imaging, such as Doppler interrogation, computerized tomography, or magnetic resonance imaging, is required to rule out invasive placentation, recognizing the limitations of such studies.^{12,24}

Recommendations

3. Ultrasound should be performed prior to induced abortion to confirm gestational age and aid in operative planning (Strong recommendation. Level of evidence: Low).
4. Placental localization by ultrasound is recommended before second trimester abortion when previa is suspected, and when there is a history of uterine scar (Strong recommendation. Level of evidence: Very low).

5. Expert consultation is advised when invasive placentation is suspected, especially in women with a uterine scar (Strong recommendation. Level of evidence: Very low).

Risk and Benefits of second Trimester Surgical Versus Medical Abortion (Table 3)

The complication rate of D&E is less than 1% before 16 weeks,²⁵⁻²⁷ 1% between 16 and 20 weeks, 1.5% over 20 weeks, increasing by 1% per week thereafter.²⁵⁻²⁷ Mortality has decreased over time to 0.65 in 100 000.²⁸ The mortality rates for D&E were 2.5 times lower than those for MA, but this difference is not statistically significant.^{25,26} D&E is associated with a lower risk of complications²⁷ than MA.²⁹ All these rates are lower than birth mortality rate of 8.8 in 100 000 live births.³⁰

Because of the increased risk of hemorrhage with PP, with or without prior CS,²⁴ SA is preferred to MA in this circumstance. If an MA takes place, urgent surgical backup should be available.

Preoperative Medications

Antibiotic prophylaxis

Although uncommon, post-abortal infections may have serious sequelae.³¹ Two systematic reviews and meta-analyses of 19 RCTs showed that antibiotic prophylaxis for first trimester SA reduces post-abort infection, with relative risks of 0.58 (95% CI 0.47-0.71)³² and 0.59 (95% CI 0.46-0.75),³³ respectively. One RCT demonstrated a slight superiority of universal prophylaxis compared with a screen and treat strategy to reduce infection (RR 1.53; 95% CI 0.99-2.36).³⁴ Few studies have examined antibiotic prophylaxis for second trimester SA, but limited findings show

benefits.³⁵ Most clinicians managing second trimester MA do not provide antibiotic prophylaxis.²⁹

No antibiotic option is superior to another – commonly doxycycline, metronidazole, and beta-lactams are used.^{33,36} The 2012 Cochrane meta-analysis found a similar risk reduction between single-dose (RR 0.63; 95% CI 0.50-0.80) and multidose regimens (RR 0.71; 95% CI 0.55-0.92) when compared with placebo.³³ Infection rates were also similar between 3- and 7-day courses of doxycycline initiated post-procedure.³⁷ In another RCT, pre-procedure initiation of antibiotics was significantly more effective than post-procedure.³⁸ As for all medication, antibiotic stewardship should be employed.³⁹

Summary Statement

2. Doxycycline, metronidazole, and beta-lactams are each suitable to reduce the risk of post-abort infection (Strong recommendation. Level of evidence: High).

Recommendations

6. Preoperative antibiotics should be given to all women undergoing surgical abortion (Strong recommendation. Level of evidence: High).

7. Women at risk or suspected to have a sexually transmitted infection should be screened at the time of abortion. If positive, the woman should receive evidence-based treatment, in addition to any pre-procedural antibiotics received. (Strong recommendation. Level of evidence: Very low).

Contraception

Since many women do not attend follow-up appointments, contraception should be offered, according to needs,

Table 3. Risks and benefits of second trimester SA versus MA

Second trimester surgical abortion	Second trimester medical abortion
1-2 days of cervical preparation before the procedure followed by a post-anaesthetic recovery time	Procedure lasting hours to days with a stay of a 1-3 days in the facility
Performed by surgical extraction	Expulsion (delivery) following repeated administration of medication
Requires a procedure room, a D&E-trained provider, skilled staff, and local/moderate sedation	Requires skilled nurses and an obstetrics trained provider
Short-term analgesics and/or anaesthesia provided before and during the procedure	Short-term or continuous analgesia provided during cervical dilation and expulsion
Likely will not provide an intact fetus for viewing/holding and may limit autopsy results	Intact fetus may be desired when viewing/holding and/or autopsy to be performed
Cremation and burial may be offered	Cremation and burial may be offered
Potential complications: Heavy bleeding, uterine perforation, infection, incomplete abortion, transfusion (<1%), hysterectomy	Potential complications: Heavy bleeding, infection, incomplete abortion requiring D&C, transfusion (<5%), hysterectomy

Adapted from Paul et al.¹²

before IA.^{40,41} Although 1 RCT demonstrated improved post-abortion contraceptive use after counselling compared with no counselling,⁴² the most effective counselling type and timing are uncertain.^{43,44}

Several RCTs and cohort studies have shown that insertion of an IUCD immediately following SA results in higher long-term use and lower rates of repeat abortion compared with delayed insertion or initiation of a different contraceptive.^{45–49}

Summary Statement

12. Immediate placement of intrauterine contraception reduces repeat abortion and unintended pregnancy compared with other methods (Strong recommendation. Level of evidence: Moderate).

Recommendation

8. Women should be offered contraception counselling before abortion, and provided with their chosen method (Strong recommendation. Level of evidence: Low).

Preoperative medications

Oral NSAIDs such as ibuprofen, diclofenac, and naproxen have all been shown to decrease intraoperative and postoperative pain in first trimester SA compared with placebo.^{50–54} Ibuprofen was superior to tramadol for postoperative pain,⁵³ and oral opioids have not demonstrated reduction in either intraoperative or postoperative pain.^{55,56} Acetaminophen⁵⁷ and ketorolac⁵⁸ did not reduce pain in women undergoing GAn.

Benzodiazepines reduced neither pain^{51,59} nor anxiety⁶⁰ when administered pre-procedure in RCTs. MISO increases preoperative cramping,^{61–66} while data regarding intraoperative pain reduction are conflicting.^{52,67,68} Antiemetic should be considered in women receiving IV opioids and women with hyperemesis.

Analgesia/Anaesthesia first and second Trimester SA

Local anaesthesia: A placebo (sham block) RCT of women not receiving sedation for first trimester SA demonstrated reduction in pain with a PCB of 20 mL 1% buffered lidocaine injected at 4 sites (2, 4, 8, and 10 o'clock) with a 3-minute wait prior to dilation.⁶⁹ A follow-up RCT found no difference in pain between immediate dilation versus waiting 3 minutes and less pain with a 4-site injection versus 2-site.⁷⁰ A Cochrane review concluded that carbonated lidocaine was superior to plain lidocaine, slow injection superior to fast injection, and deep superior to superficial injection for first trimester SA.⁷¹ In women under moderate

sedation, paracervical and intracervical injections appear to have similar effects.⁷² Total lidocaine dose should not exceed 4.5 mg/kg and not more than 7 mg/kg if epinephrine or vasopressin is added.^{73–75} Side effects of lidocaine include lightheadedness, tinnitus, circumoral tingling, and metallic taste in the mouth. Seizures, cardiac effects, and anaphylaxis are rare and dose related. Inadvertent IV lidocaine injection warrants increased monitoring for toxicity.

Sedation: Moderate sedation is commonly offered for SA, typically using fentanyl 50–100 µg IV and midazolam 1–2 mg IV. Moderate IV sedation with PCB is superior to PCB alone^{76,77} or to PCB with oral opioid/benzodiazepine.⁷⁸ Addition of nitrogen dioxide and nitrous oxide 50:50 (Entonox) does not improve procedural or postoperative pain.^{79,80}

Deep IV sedation and GAn using propofol are offered in some centres.^{71,81,82} In an RCT comparing moderate sedation plus PCB versus GAn alone, intraoperative pain control was better with GAn, but postoperative pain control was worse.⁸³ Adding a 10-mL PCB in women undergoing GAn for SA up to 21 weeks did not improve postoperative pain.⁸⁴

Non-pharmacological interventions: Evidence regarding pain reduction when listening to music has been conflicting.^{85,86} Hypnosis may reduce sedation requirement⁸⁷ and decrease the need for nitrous oxide but does not affect pain rating.⁸⁸

Summary Statement

3. Moderate sedation combined with a paracervical block provides improved intraoperative pain control compared with local anaesthesia alone (Level of evidence: High).

Recommendations

9. Women undergoing first trimester surgical abortion with no contraindications should receive non-steroidal anti-inflammatory medication (Strong recommendation. Level of evidence: High).
10. Moderate sedation combined with a paracervical block should be offered to women undergoing first or second trimester surgical abortion if possible (Strong recommendation. Level of evidence: High).

Analgesia for second Trimester MA

PCA with 50 µg fentanyl every 3 or 6 minutes was found to be superior to 25-µg fentanyl or 2-mg morphine PCA.⁸⁹ NSAIDs decreased opiate requirements.⁹⁰ Controlled trials demonstrated reduction in pain during MA when metoclopramide was added to PCA with morphine.⁹¹ PCB did not confer benefit.^{92,93}

Feticide

Feticide refers to the cessation of fetal cardiac activity prior to IA and is generally offered for psychosocial reasons (woman and provider).⁹⁴ It is achieved via:

1. transabdominal injection of pharmacological agents, such as:
 - KCl (mostly used in second trimester MA),^{95–104}
 - digoxin (mostly used before second trimester SA),^{105–120} or
 - lidocaine^{121,122}
2. digoxin administered transvaginally^{111,114,115}
3. umbilical cord transection¹²³

Feticidal agents can be injected in the amniotic fluid^{107–112,114,116–118,120} or by the intrafetal,^{98,105,106,110–112,118,120} intracardiac,^{95,97,99,101–103,113} or intrafunic route.^{96,98,121}

A GRADE approach to assessing the role of feticide was performed. Articles selected are related only to feticide prior to IA and not multifetal pregnancy reduction.

Should feticide be used prior to second trimester SA?

In 12 descriptive studies,^{96,103,105–108,110,112,115,117,118,123} where 8 to 4906 women received feticide before second trimester SA, the rate of major maternal complications (major unintended surgery, hemorrhage requiring transfusion, severe pelvic infection)¹²⁴ varied from 0^{96,117} to 3.8%.¹¹⁵ One case of hyperkalemic paralysis secondary to intra-amniotic injection of digoxin was reported.¹¹⁶ Studies reported extramural deliveries in 0% to 0.5%.^{103,110}

Two RCTs^{111,120} compared intrafetal with intra-amniotic injection of digoxin: 1 did not find any difference,¹¹¹ while the other 1 found higher rate of absent cardiac activity with intrafetal injection (94.8% vs. 82.3%; $P = 0.002$), but with a trend towards more extramural deliveries (3.8% vs. 1.5%; $P = 0.28$).¹²⁰ Side effects were common in both studies; 40% experienced fatigue or nausea and 20% experienced vomiting, lightheadedness, or palpitations.^{111,120}

According to 1 RCT,¹⁰⁹ 1 cohort study,¹¹³ and 1 time-series,¹¹⁴ the major complication rate was found to be significantly higher with feticide compared with no feticide (RR 3.73; $P = 0.002$) (Level of evidence: Moderate), with no difference in procedure time (Level of evidence: Low). Vomiting was more frequent with feticide (RR 5.05; $P = 0.03$) (Level of evidence: Low). Other outcomes could not be assessed with the GRADE approach because of limited evidence.

Summary Statement

4. Feticide prior to second trimester surgical abortion is associated with more side effects and a higher complication rate without reduction in operating time (Level of evidence: Low).

Recommendation

11. Feticide before second trimester surgical abortion may be performed following discussion of both medical and psychosocial considerations (Weak recommendation. Level of evidence: Low).

Should feticide be used prior to second trimester MA?

In 10 descriptive studies,^{95,96,100,103,105–107,121,122,125} where 21 to 1677 women underwent feticide before second trimester MA, the rate of major maternal complications¹²⁴ varied from 0% to 0.8%.^{95,96,100,105,106,121,122} Two serious adverse events were reported: 1 maternal cardiac arrest after a fetal intracardiac injection of KCl⁹⁹ and 1 case of *Clostridium perfringens* sepsis.⁹⁸ In a retrospective cohort study⁹⁹ comparing 17 women with feticide with 51 without, no difference in retained placenta, fever, and gastrointestinal side effects was noted. Women with feticide had a significant shorter time to expulsion (14.8 hours vs. 9.5 hours; $P = 0.006$) and required fewer doses of PGE₂ (2 vs. 3; $P < 0.01$). The mean GA in the feticide group was significantly greater (1 more week; $P < 0.01$).⁹⁹ In a time series¹⁰¹ comparing 64 women with no feticide before 2001 with 82 women with feticide from 2001 onwards, D&C occurred in 82.9% of women with feticide versus 65.6% of women without ($P = 0.02$). One study comparing intrafunic versus intracardiac injection¹⁰⁴ and 1 case series on funic injection of KCl⁹⁶ reported live births in spite of feticide. There was no difference in the major rate of complication, or in the duration of the induction, between studied groups.¹⁰⁴

In cases of PP, feticide may interrupt blood flow to the placenta, reducing bleeding risk.¹²⁶ Two small comparative studies in women with PP reported conflicting results regarding outcomes of MA, with 1 showing benefit in the feticide group.^{126,127}

Of note, in an acceptability study (N = 101 providers), 78% of those who attended feticide said it improved their professional practice, and 52% said it improved women’s experience.¹²⁵ This alone is sufficient to guide the decision to use feticide during IA.

Summary Statement

5. More evidence is required to determine if feticide prior to second trimester medical abortion confers benefit (Level of evidence: Very low).

Recommendation

12. Feticide may be performed prior to second trimester medical abortion, following discussion of both medical and psychosocial considerations (Weak recommendation. Level of evidence: Very low).

METHOD SELECTION AND TECHNIQUE

Early SA (<7 Weeks)

When a woman presents for early IA – prior to 7 weeks – either MA or SA is equally effective and acceptable.² Delaying SA until beyond 7 weeks (with the intention of determining viability and rule out EP) is no longer advised,¹²⁸ given the increasing risk of complications with advancing GA and the emotional stress of prolonging an unintended pregnancy.¹²⁹

Early SA can be performed by MVA or EVA with similar success and complication rates.^{130,131} The relative lack of tissue presents 2 diagnostic challenges. The first is ruling out ongoing pregnancy,^{132–134} which varies from 1.3 per 1000 under 6 weeks of gestation when performed by a skilled provider using routine preoperative and postoperative transvaginal ultrasound, direct examination of POC, and rigorous FU^{135,136} to 23 per 1000 when multiple providers are involved.¹³⁷

The second diagnostic challenge is excluding EP in the setting of a PUL, when a yolk sac (and, in some instance, a definite GS) has not been seen. Early SA may provide confirmation of IUP if villi are identified on tissue exam. A PUL, unless intraoperatively confirmed to be an IUP, should be followed with serial serum β -hCG. A 50% drop in levels is expected within 24 hours following successful pregnancy evacuation.^{128,135–138}

While some studies suggest slightly higher pain ratings in early SA,^{139,140} these can be performed using local anaesthesia.

Recommendations

13. Early surgical abortion (<7 weeks) should be provided with routine preoperative and postoperative ultrasound, direct examination of products of conception and β -human chorionic gonadotropin follow-up when products of conception are not identified (Strong recommendation. Level of evidence: Low).
14. For women who cannot or refuse serial β -human chorionic gonadotropin follow-up following early surgical abortion, the procedure should be delayed until an intrauterine pregnancy can be confirmed (Strong recommendation. Level of evidence: Very low).

First Trimester SA (7 to <14 Weeks)

First trimester SA is one of the most common and safe surgical procedures performed in Canada,^{1,141} with a risk of serious complications under 0.2%.^{1,25,28,142–144} Use of a *no touch* technique and antibiotic prophylaxis reduce the risk of infection.^{32,33,36,145} Routine IV access for first trimester SA is not required,^{3,146–148} but most providers recommend it.

Although performed by most clinicians,¹⁴⁹ and recommended by 1 guideline,¹⁴⁷ routine cleansing of the cervix is not supported by studies.¹⁵⁰

Gentle cervical dilation should be achieved before the introduction of an aspiration cannula^{3,147,151,152}; Pratt or Denniston dilators are effective and exert lower force on cervical tissue than Hegar dilators.^{3,152,153} The selected cannula is typically the same diameter in millimetres as GA in completed weeks (eg, 9 mm up to 9 weeks 6 days), or 1 mm smaller. Abortion by sharp curettage (D&C) is obsolete,^{3,147,151,154} and sharp curettage should not be routinely performed in first trimester SA.^{3,147,149,151,155} Both MVA and EVA are safe and effective.^{3,130,147,151}

Blood loss is typically minimal,^{156,157} even in women on anticoagulant therapy.¹⁵¹ There is no evidence that anticoagulants need to be stopped for SA prior to 84 days.¹⁵⁶ Immediate examination of the aspirated uterine contents should be done at the time of the procedure to identify POC.^{3,147,151}

Cervical dilation prior to first trimester abortion

Routine cervical priming is not recommended^{3,41,151,152} because it adds delay, is associated with side effects, and the baseline complication rate is very low. However, nulliparous women with a late first trimester gestation and women with uterine anomalies or known cervical stenosis may benefit from cervical priming.¹⁵² Cervical preparation agents include synthetic osmotic dilators (ODs), laminaria, prostaglandins (PGE₁, PGE₂, PGF_{2 α}), MIFE, and NO donors. Use of pharmacological agents requires informed consent owing to the risk of anomalies if pregnancy continues.

Three Cochrane reviews,^{158–160} 1 comprehensive review,¹⁵² and a few additional RCTs^{131,161–163} have been published on cervical priming prior to first trimester SA. The following conclusions were reached:

- When compared with placebo, cervical dilation was improved when MISO, gemeprost, MIFE, dinoprostone, carboprost, and NO donor were used.^{152,158–160}
- Compared with placebo, MISO significantly reduced procedure time and force required for dilation and blood loss, although side effects such as nausea and/or cramping were significantly higher.^{162,158,159,164} There is a significant reduction in incomplete abortion as well (0.78% vs. 2.26%; RR 0.35; 95% CI 0.21–0.58, number needed to treat = 68).¹⁶⁴

Based on data from comparative studies, the following conclusions can be made about MISO:

- MISO 400 µg is superior to MISO 200 µg^{158,162} or gemeprost 1 mg.¹⁵⁸
- Vaginal and sublingual routes are superior to oral,^{158,163} and sublingual are superior to vaginal.¹⁵⁸
- Effectiveness and side effects of MISO increase with dosage.¹⁶² One recent RCT¹⁶¹ did not find differences among oral, vaginal, and sublingual administration of MISO 400 µg 1.5 to 4 hours pre-procedure; however, side effects, such as nausea and diarrhea, were significantly more frequent in the sublingual group.¹⁶¹
- There are no comparative studies on buccal MISO for cervical priming in first trimester SA.
- The most effective timing of MISO is 3–4 hours vaginally^{152,158} or 2–3 hours sublingually pre-procedure.¹⁵⁸

With respect to other forms of cervical ripening:

- MIFE 200 mg 24–48 hours orally prior is superior to MISO 600 orally or 800 µg vaginally 16–24 hours pre-procedure without a difference in side effects.¹⁵⁸
- Laminaria is superior to PGF_{2α} or Gemeprost 1 mg administered 3–4 hours pre-procedure; PGF_{2α} is associated with unplanned expulsions prior to procedure.¹⁵⁸

No difference in initial dilation was observed:

- between MISO 200–400 µg 4 hours pre-procedure and overnight laminaria,¹⁵⁸ OD,¹⁵⁹ or PGF_{2α} 125 µg IM 2 hours prior to procedure.¹⁵⁸
- between gemeprost 1 mg and OD inserted 3–4 hours prior to procedure.¹⁵⁸

NO donors are inferior to prostaglandins,¹⁶⁰ including MISO¹⁵⁹ or use of prostaglandin plus NO.¹⁵⁶ NO donors are associated with more bleeding and more side effects.¹⁶⁰

Recommendations

15. Cervical preparation is not routinely required prior to first trimester surgical abortion (Strong recommendation. Level of evidence: Moderate).
16. Cervical priming before first trimester surgical abortion may be considered in nulliparous women and when cervical dilation is expected to be difficult (Weak recommendation. Level of evidence: Very low).
17. The following are recommended cervical preparation regimens (Strong recommendation. Level of evidence: High):
 - a. misoprostol 400 µg vaginally 3 hours pre-procedure; or
 - b. misoprostol 400 µg sublingually, 2–3 hours pre-procedure; or

- c. laminaria placed intracervically 6–24 hours pre-procedure; or
- d. synthetic osmotic dilator placed intracervically 3–4 hours pre-procedure; or
- e. mifepristone 200–400 mg orally, 24–48 hours prior to procedure.

Second Trimester SA (≥14 Weeks)

D&E consists of cervical preparation, dilation, and extraction with a combination of aspiration and forceps. It is safe when performed by trained clinicians. Routine cervical preparation is recommended, as are IV access, no touch technique, and rapid access to uterotonics.³ Very high doses of oxytocin are required to obtain any significant clinical effect on uterine tone.¹⁶⁵ Direct examination of uterine contents should take place at the time of the procedure. When compared with first trimester procedures, second trimester SA is associated with more complications, which increase with advancing GA.^{163,164,166}

Does prophylactic vasopressin reduce blood loss in second trimester SA?

Two RCTs^{167,168} assessed the use of vasopressin for second trimester SA. In 1 RCT,¹⁶³ vasopressin 4 units in 20 mL of local anaesthetic (n = 181) compared with placebo (n = 156) significantly reduced blood loss from D&E, without increasing blood pressure (Level of evidence: Moderate). Beyond 15 weeks, vasopressin was associated with a lower likelihood of blood loss >250 mL.¹⁶³ A small RCT¹⁶⁴ in women with a mean GA of 16.8 weeks showed that paracervical vasopressin (n = 13) compared with placebo injection (n = 15) did not result in significant changes in uterine pulsatility or blood loss (Level of evidence: High).

Both the National Abortion Federation and the Society of Family Planning clinical guidelines recommend the use of dilute intracervical vasopressin to reduce blood loss for second trimester SA.^{3,166} Adverse effects of vasopressin are rare and self-limiting (high blood pressure, bradycardia, etc.).^{169,170}

Summary Statement

6. Intracervical vasopressin may reduce blood loss in second trimester surgical abortion (Level of evidence: Low).

Recommendation

18. Vasopressin 4 units in 20 mL for cervical local anaesthesia may be considered during second trimester surgical abortion to reduce blood loss (Strong recommendation. Level of evidence: Low).

Cervical dilation prior to second trimester SA

Laminaria/ODs are routinely used in second trimester SA.^{62,171,172} They reduce the risk of cervical laceration: from 14–18 weeks, the risk decreases from 0.8% to 0.4%, and at 18–20 weeks, the risk is reduced from 5% to 1.6%.^{173,174} A GRADE approach was used to answer the following question:

Should MISO, laminaria/ODs, MIFE, or a combination of previous options be used prior to second trimester SA?

Early second Trimester SA (Before 17 Weeks)

MISO versus laminaria/ODs: Two retrospective case studies^{175,176} and 2 RCTs^{62,177} compared the use of buccal MISO 400 µg or 600 µg, 3–4 hours pre-D&E with the use of overnight ODs and showed no difference in procedure time. One RCT⁶¹ reported a significantly longer procedure time with vaginal MISO alone compared with laminaria. Three RCTs^{61,62,177} reported that women using MISO alone had a lower baseline dilation or required additional dilation before D&E compared with those using ODs. One RCT⁶³ showed no benefit in procedure time when MISO was added to laminaria. One lower-quality retrospective cohort study¹⁷⁸ showed that improved baseline dilation when laminaria was added to pre-procedural MISO.

Complication rates were similar between MISO and ODs (4.02% vs. 3.2%, chi square test; $P = 0.63$).^{61–63,176,178} However, women using MISO reported more pain before D&E,^{61–63} more chills^{61,178} and more diarrhea.^{177,178} Women using laminaria reported more pain overnight in 1 study.⁶¹

Physicians rated procedures significantly harder when cervical preparation was done with MISO alone^{61,62,177,178} compared with ODs (with or without MISO). Overall satisfaction of physicians and women was identical between groups.⁶² In 1 study,⁶¹ women preferred MISO over overnight laminaria because of shorter overall procedure time.

Summary Statements

7. For early second trimester surgical abortion, use of buccal/vaginal misoprostol 400 µg 3–4 hours before dilation and evacuation:
 - a. may not achieve as much dilation as osmotic dilators alone (Level of evidence: Moderate).
 - b. results in similar complication rates as for osmotic dilators, but does increase side effects (Level of evidence: Medium).
 - c. reduces ease of procedure compared with use of osmotic dilator (Level of evidence: High).

Recommendation

20. For early second trimester surgical abortion, cervical preparation can be achieved with laminaria/synthetic osmotic dilators alone or misoprostol 400 µg 3–4 hours pre-procedure (Strong recommendation. Level of evidence: Moderate).

MIFE: Two studies comparing MIFE with other cervical preparation methods were identified. One RCT¹⁷⁹ compared MIFE 200 mg orally ($n = 24$) with ODs ($n = 25$) for overnight cervical preparation at gestation of 14 to 16 + 6 weeks. No difference was shown in procedure time, but baseline dilation and ease of procedure were significantly greater when ODs were used. One unintended fetal expulsion and significantly more pain and diarrhea were experienced in the OD group. Women's satisfaction was higher with MIFE.

Another RCT¹⁸⁰ compared oral MIFE 200 mg (36 hours before SA) plus oral MISO 400 µg (3 hours prior) with 2 groups receiving either MIFE or MISO alone, for gestations of 12 + 1 to 14 + 3 weeks. Procedure time was reduced, baseline dilation increased, and intraoperative bleeding was less in the combined MIFE-MISO group. Rates of hemorrhage and side effects were similar in all groups. Ease of procedure and satisfaction were rated higher by physicians in the MIFE-MISO group. Women's satisfaction did not differ between groups.

Summary Statement

8. More research is required to state whether use of mifepristone confers benefit for cervical dilation prior to early second trimester surgical abortion (Level of evidence: Very low).

Recommendation

21. For early second trimester surgical abortion, mifepristone is not recommended for cervical preparation (Weak recommendation. Level of evidence: Very low).

Later second trimester SA (17–24 weeks)

MISO versus laminaria/ODs: Two RCTs compared use of overnight laminaria alone with MISO 400–800 µg buccally 3–4 hours pre-D&E¹⁷⁷ or 600 µg vaginally overnight.¹⁸¹ Four RCTs compared use of ODs alone with MISO 400 µg buccally 3 hours pre-D&E plus ODs for 2 days,⁶⁴ overnight,^{63,65} or the same day.⁶⁶ Another cohort study¹⁷⁸ compared MISO with MISO plus overnight laminaria. Inconsistent effects on procedure time were observed,^{63,64,177,181} although MISO plus overnight ODs reduced procedure time among nulliparous women.⁶⁵ Most

studies showed that baseline dilation was higher when MISO was added to an ODs regimen.^{63–65,177,178}

The addition of MISO to dilators does not decrease complication rates (7.88% vs. 9.02%, chi square test; $P = 0.559$).^{63–66} However, women using MISO reported more pain 3–4 hours before D&E, more analgesic requirement,^{63–66} and more side effects (nausea,^{64,181} chills^{64,65,178} and diarrhea^{177,178}). The risk of unscheduled fetal expulsion occurred more often when overnight MISO was given.¹⁸¹

Inconsistent effects on ease of procedure were reported.^{63–65,177,178,181} In 1 study, 25% of women in the MISO plus laminaria group versus 6% in the laminaria alone group found this abortion worse than a prior second trimester abortion ($P = 0.04$).⁶⁴ In 2 other studies, satisfaction of women was identical between groups.^{65,66}

Summary Statements

9. For late second trimester surgical abortion, use of buccal misoprostol 400 µg 3–4 hours plus laminaria/synthetic osmotic dilators before dilation and evacuation:
 - a. achieves significantly more dilation than osmotic dilators alone without influencing procedure time (Level of evidence: Moderate).
 - b. does not decrease severe complications (Level of evidence: Moderate) compared with use of osmotic dilator alone, but may increase side effects such as pain, nausea, chills, and diarrhea (Level of evidence: Low).

Recommendation

22. For late second trimester surgical abortion, the use of misoprostol 400 µg 3–4 hours pre-dilation and evacuation in addition to serial insertions of osmotic dilators is recommended but is associated with side effects (Strong recommendation. Level of evidence: Moderate).

MIFE: Five RCTs using MIFE before late gestation D&E were identified. MIFE 200 mg orally was used overnight,⁶⁵ or 48 hours pre-procedure,¹⁸² along with ODs,⁶⁵ buccal/sublingual/vaginal MISO 400 µg 1.5–6 hours pre-procedure,^{182–184} or both.^{182,185} Comparator groups were overnight OD alone,^{65,183} serial sets of ODs plus buccal MISO 400 µg 90 minutes pre-procedure,¹⁸⁵ vaginal/sublingual MISO 600 µg 1.5–2.5 hours pre-D&E with or without ODs,¹⁸² or vaginal MISO alone 400-µg 4–6 hours pre-procedure.¹⁸⁴

Procedure time was not different among groups in 3 RCTs^{183–185}; however, in 1 RCT, 1 less day of cervical

preparation was required when MIFE was added to ODs and MISO.¹⁸⁵ Procedure time was significantly shorter in the MIFE groups in 2 RCTs.^{65,182} Baseline dilation and side effects were variable across studies.^{65,182–184} Complications rates reported in 2 RCTs^{65,185} were 3.3% in the MIFE groups versus 9% in non-MIFE groups (Fisher exact test; $P = 0.11$). In 1 RCT, 9 unscheduled fetal expulsions before D&E were reported, but MIFE was given 48 hours pre-procedure ($n = 877$).¹⁸²

Ease of procedure was assessed as identical in both groups in 2 RCTs,^{183,185} while physicians' satisfaction was higher with MIFE groups in 2 RCTs.^{65,184} Satisfaction of women was either equal between groups^{65,185} or higher in the MIFE groups.^{183,184}

Summary Statement

10. For late second trimester surgical abortion, use of mifepristone overnight with osmotic dilators and/or buccal/sublingual/vaginal misoprostol 400 µg 3–4 hours before dilation and evacuation facilitates cervical preparation and decreases procedure time (Level of evidence: Low).

Recommendation

23. For late second trimester surgical abortion, use of mifepristone 200 mg orally overnight is recommended, in addition to osmotic dilators and/or misoprostol 400 µg 3–4 hours pre-procedure (Weak recommendation. Level of evidence: Low).

Second Trimester MA

Second trimester medical abortion consists in the use of medications that induce fetal expulsion. It may be preferred to D&E, and indeed offered, when an intact fetus is preferred for psychosocial or diagnostic indications. It is commonly performed in a hospital setting as induction may take more than 24 hours. While the regimens discussed may be considered in the setting of midtrimester fetal demise, only evidence pertaining to abortion was reviewed. The following regimens are inappropriate for midtrimester induction where a live birth is desired.

The World Health Organization–recommended MISO regimens are as follows^{186,187}:

- 13–24 weeks: MISO 400 µg vaginal/sublingual/buccal every 3 hours
- 25–28 weeks: MISO 200 µg vaginal/sublingual/buccal every 4 hours
- >28 weeks: MISO 100 µg vaginal/sublingual/buccal every 6 hours

Cervical dilation prior to second trimester MA

Since induction requires significant resources, cervical ripening may decrease time to expulsion and cost. A GRADE approach was used to answer the following question:

Should mechanical dilation, ODs, MISO, NO, MIFE, or a combination of previous options be used prior to second trimester MA?

Mechanical dilation: One retrospective¹⁸⁸ and 4 prospective cohort studies^{189–192} examined use of intracervical catheters prior to induction with MISO. When compared with no preparation, the use of a double-balloon catheter was associated with similar induction-to-expulsion times (21.1 hours vs. 23.1 hours; $P = 0.393$).¹⁸⁸ When compared with no cervical preparation, adding an intracervical catheter was not associated with a decrease in time to expulsion in 2 studies,^{189,190} and a reduced duration in 1 study (7.5 hours [combined] vs. 11.76 hours [cervical preparation with MISO] vs. 19.76 hours [catheter]; $P < 0.0001$).¹⁹¹ Catheter traction is superior to no traction.¹⁹² In all studies, complication rates were similar among groups.

ODs: Seven studies^{193–199} were identified where ODs were evaluated prior to second trimester MA. In 3 cohort studies^{193–195} and 2 RCTs,^{196,197} laminaria compared with no OD yielded limited reduction in time to expulsion. Conversely, in 2 cohort studies^{193,194} and 1 RCT,¹⁹⁶ comprising 151 women, there was an overall increased duration in time to expulsion using laminaria with or without MISO versus MISO alone (18.1 vs. 15.4 hours; $P < 0.001$). In 1 time series on 174 women, adding laminaria to MIFE-MISO resulted in shorter time to expulsion (7.5 hours vs. 12.7 hours; $P = 0.001$) and time in hospital (3 days vs. 4 days; $P < 0.001$).¹⁹⁵ In an RCT comparing laminaria to MIFE prior to induction, laminaria was associated with more pain and longer time to expulsion (10 hours vs. 16 hours; $P = 0.01$).¹⁹⁸ Laminaria reduced time to expulsion compared with no preparation in 1 RCT where PGE₂ was used for induction.¹⁹⁹

MISO: In 1 pilot study comparing 19 women who self-administered MISO 50 µg buccally the evening prior to MISO induction with a historical cohort not receiving such preparation,²⁰⁰ median time to expulsion was 33% less when MISO priming was used; however, 3 women experienced nausea and 11 had cramping overnight. No unintended expulsion occurred prior to induction. Two small RCTs comparing oral MISO 400 µg versus placebo or no treatment prior with MISO²⁰¹ or gemeprost²⁰² induction reported conflicting results on time to expulsion.

NO donors: In an open-label RCT (50 women), time to expulsion was reduced by 8 hours with isosorbide

mononitrate prior to MISO induction compared with no preparation.²⁰³ In a placebo-controlled RCT (100 women), no significant difference was found in time to expulsion.²⁰⁴ Complications rates were similar between groups in both studies.

MIFE: Four RCTs, comprising 610 women, demonstrated significant reductions in time to expulsion (–2 to –10 hours) when additional MIFE 200 mg was added to prostaglandin/oxytocin regimens, with similar rates of expulsion and side effects.^{205–208} In most cases, MIFE was administered approximately 24 hours before admission. In a case series of 999 women, 2 had unintended expulsion prior to induction (0.2%).²⁰⁹

Two RCTs (99 women) showed that MIFE reduced time to expulsion by 3.5 to 6 hours when compared with laminaria priming and was associated with less pain.^{198,210}

We identified 9 studies and 1 systematic review comparing the interval between MIFE and MISO administration for induction.^{211–219} Simultaneous MIFE and MISO administration (2 RCTs) was associated with longer MISO-to-expulsion time by 5.1–5.3 hours when compared with administration of MIFE 24–36 hours prior to MISO induction.^{211,212} In a 3rd RCT, administration of MIFE within 12 hours of MISO induction resulted in lower likelihood of expulsion within 12 hours, but similar rates at 24 hours.²¹³ Three RCTs and 2 cohort studies (752 women) compared 1- and 2-day MIFE-MISO intervals, showing either no or modest reduction in time to expulsion in the 48 hour-interval group (less than 2 hours).^{214–218} In 1 cohort study using gemeprost induction, prolonging the MIFE interval to 72 hours resulted in longer time to expulsion.²¹⁹

Summary Statements

11. For second trimester medical abortion:
 - a. use of mifepristone 24–48 hours prior to induction reduces time to expulsion without added side effects (Level of evidence: High).
 - b. mechanical dilation with intracervical catheters prior to induction rarely confers benefit (Level of evidence: Low).
 - c. laminaria/synthetic osmotic dilators prior to induction do not confer any benefit and may increase both pain and time to expulsion (Level of evidence: Moderate).

Recommendations

24. For second trimester medical abortion, use of mifepristone 24–48 hours prior to misoprostol induction is recommended (Strong recommendation).

Level of evidence: High). The specific timing of mifepristone should be based on provider and patient preference (Weak recommendation. Level of evidence: Moderate).

25. For second trimester medical abortion, use of mechanical dilation or osmotic dilator prior to induction is not recommended (Strong recommendation. Level of evidence: Low). Mechanical dilation may be considered when other cervical priming approaches must be avoided (Weak recommendation. Level of evidence: Low).
26. For second trimester medical abortion, there is insufficient evidence to recommend the use of nitric oxide donors or misoprostol priming prior to induction (Weak recommendation. Level of evidence: Low).

Additional Considerations in Late second Trimester IA

Previa: in the setting of PP, SA is preferable to MA as it is associated with lower blood loss.²²⁰ Laminaria can be inserted as an outpatient in the presence of an asymptomatic PP.²¹⁶ Use of intracervical vasopressin and rapid removal of the placenta are recommended to reduce hemorrhage and perforation.

Recommendation

27. In the presence of placenta praevia, intracervical vasopressin, ultrasound guidance, and rapid removal of the placenta are recommended. Expert backup is advised in case of significant bleeding (Strong recommendation. Level of evidence: Very low).

Fetal anomalies: In cases of fetal anomalies, a stillbirth is not guaranteed unless feticide takes place, therefore; neonatal palliative care should be offered prior to induction.²²¹ To aid with grieving, many facilities have implemented measures to help women and families.²²² These include mementos such as footprints, ultrasound pictures, and identification bracelets, which can be provided whether the woman chooses SA or MA.

Stillbirths: In Canada, a stillbirth occurs after expulsion of a fetus greater than 20 weeks or 500 g. Some consider that “The process for the registration and reporting of therapeutic abortions should be separate from that for spontaneous fetal deaths.”²²³ In all jurisdictions, any stillbirth must be reported to Vital Statistics, recorded by a Certificate of Death, and be disposed of appropriately (cremated or buried).

Histopathology

Routine histopathological examination has been historically recommended for the detection of GTN, aneuploidy, and confirmation of an IUP.^{224,225} Currently, ultrasonogra-

phy, highly sensitive β -hCG serum testing, and gross examination of POC cost less and can identify tissue,^{226,227} even in very early abortions.^{135–137}

Although baseline risk of GTN in women undergoing abortions is not higher than in the general population (1 in 2699 cases in a Canadian study),^{228,229} women with unidentified GTN are more likely to have delayed diagnosis and subsequent complications from invasive disease.²²⁸ Therefore, histopathological examination of POC remains important in cases of abnormal exam or when GTN or EP is suspected.⁴⁰ Cytogenetics should also be performed when genetic diagnosis is required.

Standard POC examination: Immediately following the procedure, the aspirate is placed in a glass container with a small amount of water, or, if further analysis (eg, chromosomes) is needed, saline. Acetic acid may also be used. Examination is most often performed with backlighting, such as an X-ray view box placed flat on the countertop. Decidual tissue is clear, light colored, or reddish brown, and the decidua capsularis is an opaque sheet with hemorrhagic areas. The GS is thin, transparent, and can be fragmented. Chorionic villi are transparent frond-like projections that appear fluffy or feathery.^{138,230} When blood and clots impede visualization, the tissue should be rinsed until good visualization is possible.

Prior to 7 weeks, confirmation of completion requires visualization of both sac and villi.¹²⁸ POC volume or weight poorly correlates with GA.^{132,231} A GS, decidua, chorionic villi, and small fetal parts can be seen by 9 weeks of gestation. In the second trimester, major fetal parts including the calvarium, pelvis, spine, 4 extremities, and adequate placental tissue for gestational age must be visualized to confirm completion of the procedure.^{147,232} If a discrepancy occurs between POC examination and pre-procedure GA, foot length should be used for fetal dating.^{138,233–235}

Abnormal exam: When examination is inconsistent with preoperative assessment, retained POC must be ruled out, and imaging or reaspiration is mandated. If possible, ultrasound guidance should be used for reaspiration.

In early pregnancies or PULs when POC examination is inconclusive, serial β -hCG measurements should be used to rule out ongoing or ectopic pregnancy.

Hydropic villosities are associated with GTN or aneuploidy. In these cases, the specimen should be sent for histological analysis, and proper FU arranged. Women with persistent bleeding or who have not resumed their periods within 8 weeks must also be reassessed for ongoing pregnancy or GTN.

Recommendations

28. Routine gross examination of uterine contents should be performed immediately after induced abortion (Strong recommendation. Level of evidence: Very low).
29. Histopathological examination of products of conception must be performed when gestational trophoblastic neoplasia or ectopic pregnancy is suspected (Strong recommendation. Level of evidence: Very low).

POST-ABORTION CARE

Following SA, patients must be continuously observed until discharge criteria (Aldrete score²³⁶) are met, which varies by procedure and anaesthetic. Women should receive written information including normal findings, self-care, and warning signs of complications (Table 4). A 24/7 emergency number should be provided to the patient.

Following IA, most women feel normal emotionally and physically. Urine pregnancy tests may remain positive up to 60 days,^{237,238} and are not recommended as part of FU. Pregnancy symptoms generally subside within 24–48 hours,²³⁹ and the uterus involutes rapidly. Bleeding is variable but is usually less than menstrual flow. While some women experience no bleeding, bleeding and cramping may transiently increase 4–10 days after the procedure, and, if self-limiting, does not indicate a complication.²³⁹ By 2–3 weeks, most women have stopped bleeding. Unscheduled bleeding may persist due to initiation of contraception. Like bleeding, cramping can be variable and is likely attributed to uterine involution.²³⁹ Cramping may occur with or without bleeding and is generally relieved with NSAIDs. Routine prescribing of opioids is inappropriate.

In many studies, the dominant emotional reaction after IA is relief,^{240,241} including after second trimester, although data are limited.^{234,235,240,241} Because some women experience mood symptoms following any pregnancy outcome, clinicians should be attentive to women with pre-existing mental illness,

postpartum depression, or premenstrual dysphoria.^{242,243} Women terminating a wanted pregnancy because of fetal anomaly may benefit from short-term grief counselling.

Immediate Complications

Complications of surgical abortion

Failed attempted abortion: Failed attempted abortion is rare (0.15%).²⁴⁴ If a failed attempt occurs before disruption of the pregnancy (patient is stable and not bleeding), a repeat attempt should be planned after pre-treatment with MISO, MIFE, or ODs.^{245,246}

If dilation becomes difficult and the pregnancy has been disrupted or there is bleeding (or another reason that immediate completion is necessary), os finders, and ultrasound-guided insertion of rigid dilators may be helpful. For more advanced gestations, simultaneous insertion of more than 1 large rigid dilator may allow passage of D&E forceps to facilitate tissue extraction. Many providers employ ovum forceps when there is inadequate dilation for second trimester procedures at the expense of increased passes.

In cases of marked obesity, hip flexion, increased uterine traction, use of Moore-Graves vaginal speculum, lateral retractors, steel cannula extender, and long forceps may help. When there is uterine anomaly, a markedly anteflexed or retroflexed uterine body, or a tortuous cervical canal, use of flexible cannula may be useful. Flexible hysteroscopy has also been utilized to enter the uterine cavity. MA may need to be considered to complete the termination.

Hemorrhage: Hemorrhage at the time of abortion is inconsistently defined and includes >250 mL, >500 mL, hemodynamic instability, or requiring transfusion.¹⁶⁶ In the United States, between 2011 and 2013, the Centers for Diseases Control and Prevention reported 6 deaths among abortion patients related to hemorrhage. Of these, 3 were related to perforation/cervical laceration, 2 to atony, and 1 was unspecified.¹⁴⁴

Risk factors for hemorrhage at the time of abortion can be classified as¹⁶⁶:

- Moderate risk: 2 or more CSs, PP following previous CS, bleeding disorder, history of postpartum hemorrhage not requiring transfusion, GA beyond 20 weeks, large fibroids, obesity.
- High risk: suspicion of abnormal placentation, history of postpartum hemorrhage requiring transfusion, clinician concern.

When determining causes of hemorrhage, the “Four Ts” (Tone, Trauma, Tissue, Thrombin) still apply, with atony

Table 4. Warning signs of complications following IA

Symptoms	Severe pain not controlled by analgesics Feeling sick with flu-like symptoms (weakness/ faintness, nausea, vomiting, diarrhea) Continuing symptoms of pregnancy Depressive symptoms and suicidal ideation
Signs	Soaking 2 maxipads per hour for 2 consecutive hours Severe pain not reduced by common analgesics Orthostatic symptoms: lightheadedness, fainting Fever more than 38°C lasting more than 6 hours Abnormal foul-smelling vaginal discharge Absence of menstruations for 8 weeks after IA

Table 5. Management of hemorrhage at the time of abortion

Steps: Re-evaluate at each step and determine next best step	Actions
1 – Identify risk factors	Determine if preoperative planning is needed or if patient is suitable for facility.
2 – Recognize bleeding and ask for help	Establish IV access and start IV fluids; consider complete blood count and group, crossmatch, coagulation profile, and screen. If unstable, CALL CODE or PREPARE FOR A TRANSFER. Obtain medications: • MISO 200 to 600 µg sublingual/buccal/rectal × 1 • Methylergonovine 0.25 mg IM q2h – DO NOT ADMINISTER IV • PGF _{2α} 0.25 mg IM or intracervical × 8 • Oxytocin 20–40 units in 250–500 mL IV if GA over 16 weeks If under GAn: notify anaesthetist and reduce inhaled anaesthetics.
3 – Palpation	Apply direct pressure to uterus with sponge stick/hand and fundal pressure.
4 – Inspection	To explore the source of bleeding, perform “cannula” test: insert cannula to fundus and slowly withdraw until brisk bleeding ensues. If bleeding is coming from the cervix, consider urgent embolization or laparotomy. If external laceration, repair under local anaesthesia.
5 – Retained POC	Re-examine tissue – re-image ultrasound – reaspirate
6 – Intervention	Intrauterine balloon tamponade Emergent referral to gynaecology (if needed) Laparoscopy if perforation suspected Laparotomy if unstable

Adapted from Hamilton Health Sciences Protocol with permission.²⁴⁸

being most common in the second trimester.²⁴⁷ Procedure-specific causes include perforation, cervical laceration, retained POC and atony, and less commonly, abnormal placental, arteriovenous malformation, and DIC.

Each facility should have a hemorrhage protocol (eg, Table 5), access to resuscitation medications, and a transfer protocol if out of hospital.

Bleeding from the tenaculum site responds well to direct compression. If there is increased bleeding from the uterus, direct bimanual compression, compression with a sponge on a stick with fundal counterpressure, or intrauterine tamponade (catheter) will improve tone and reduce bleeding.

A low threshold for reaspiration should be maintained as retained POC can cause brisk bleeding, and aspiration encourages compression of the placental bed (Table 5). If there is suspicion of a high cervical laceration or perforation, transfer should be arranged. Embolization by interventional radiology, if available, is preferred. If unavailable, laparoscopy or laparotomy may be required.

Uterine Perforation: The risk of UP with SA is around 1–4 in 1000 cases,^{29,151} most commonly occurring during dilation for first trimester SA and with forceps evacuation in second trimester SA. The risk increases with uterine anomalies, marked uterine flexion, cervical stenosis, inadequate cervical, difficult or prolonged uterine evacuation, or less experienced providers.^{246,249} For advanced gestations or when the cervix is stenotic, cervical preparation decreases the risk of cervical trauma and perforation compared with mechanical dilatation alone.²⁵⁰ In 2 retrospective analyses, underestimation of the duration of pregnancy, inadequate cervical dilation, and failure to use ultrasound during the procedure were associated with UP.^{22,251}

In practice, UP often is often unrecognized and does not need further intervention.¹⁴⁷ Special management (Table 6) should be considered if any of the following occurs:

- woman experiences sudden pain during the procedure
- instruments pass without resistance further than expected
- contact with the gritty surface of the endometrium lost
- fat or bowel brought down with the suction or identified on gross examination
- bleeding in excess of what is expected,
- persistent post-procedural pain especially if lateralized or associated with rebound tenderness
- suspicion of a possible lateral perforation
- unstable vital signs present following completion of the procedure
- missing fetal parts following D&E when uterus feels empty

Cervical trauma: In the second trimester, cervical laceration occurs in approximately 0% to 2% of SAs¹⁷³ and is a potentially severe complication. Risk increases with increasing GA, history of cervical surgery (eg, conization), and cervical/uterine abnormalities. Cervical preparation reduces the risk of laceration, particularly at 18+ weeks.¹⁷³ Superficial laceration related to tenaculum use and application of local anaesthetic is normal during an abortion and can be observed. Persistent tenaculum site or injection site bleeding is most easily rectified by applying pressure or compression with a sponge stick or a ring forceps. If a laceration is bleeding, or is large (>1 cm), it should be repaired with an absorbable suture.

Table 6. Management of suspected uterine perforation^{3,245,252}

Stop the procedure immediately; evaluate and reassess the patient.	
If vital signs are not stable, IV fluids should be started. Evaluate with ultrasound or laparoscopy. Prepare for a transfer to hospital if necessary.	
If the uterine perforation occurs and the pregnancy is <i>disrupted</i>	Complete the procedure under laparoscopic guidance as soon as possible in order to evaluate visceral injury, to assess bowel integrity, and ensure internal bleeding is controlled.
If the uterine perforation occurs and the pregnancy is <i>not disrupted</i> and the patient is stable with no signs of hemorrhage or injury	Complete the procedure with either ultrasound or laparoscopic guidance, either immediately or after a 1–2 week-delay to allow for uterine healing.
If the procedure is thought to be <i>complete</i> when uterine perforation is suspected	Evaluate the patient: <ul style="list-style-type: none"> • If there are stable vital signs, no sign of visceral injury, minimal bleeding (<200 mL): close observation. • Uterotonics and antibiotics may be considered. • In select cases where patient is stable after 2–4 hours: patient may be discharged with close FU plans and instructions to seek emergent care if they develop concerning symptoms.
If bowel or omentum is visualized at the cervix or brought into the uterine cavity	Leave tissue in situ to identify and repair of bowel as well as the uterus. These patients must be evaluated by laparoscopy or laparotomy and may require surgical consult.
If there is suspicion of a lateral perforation	Transvaginal ultrasound and/or laparoscopic evaluation should be performed owing to the risk of retroperitoneal bleeding

While external lacerations are largely benign, internal ones are more serious as they can result in significant bleeding. Visible lacerations can be repaired vaginally when possible; higher cervical tears may require urgent embolization or laparoscopy. Cervical laceration can be diagnosed in part using a cannula test (Table 5).

Repeat aspiration: A systematic review of 36 studies reported that $\leq 3.0\%$ of SAs required repeat immediate or delayed aspiration.²⁵³ Reaspiration is indicated for ongoing pregnancy, retained POC, hemorrhage, and hematometra.^{128,254}

Hematometra is the result of an accumulation of blood in the endometrial cavity that the uterus is unable to expel. Women present with increasing pelvic pain (some women report deep pressure or rectal pain), absent or decreased vaginal bleeding, and, at times, hemodynamic compromise. This may develop immediately after abortion or insidiously over 2–3 days. It occurs at a rate of 2 per 1000 SAs²⁴⁵ and may be treated with repeat aspiration.^{245,255}

DIC: DIC results from activation of clotting and fibrinolytic systems and leads to hemorrhage, end-organ ischemia/necrosis, hypotension, and microangiopathic hemolysis.²⁵⁶ It is rare, affecting about 0.2% of second trimester abortions.²⁵⁷ Risk factors include advanced GA, intrauterine fetal demise (particularly if remote), previous abruption, abnormal placentation, amniotic fluid embolization, and blood transfusion.^{145,256} Amniotic fluid embolism is rare but often

fatal, occurring in 1 in 8000 to 1 in 80 000 pregnancies.²⁵⁸ DIC often manifests after a few hours: in a case series of 24 women with idiopathic DIC, the mean time to presentation was 153 minutes following D&E.²⁵⁷ The clinician may be alerted to DIC in the setting of ongoing oozing despite adequate management, blood that does not clot in a basin, or a significant decrease in hemoglobin compared with pre-procedure.

Management consists of inpatient correction of hypovolemia, factor replacement, typically fresh frozen plasma, and treatment of underlying cause. Platelets should be replaced only if there is significant thrombocytopenia. The benefit of recombinant factor VII must be weighed against the lack of evidence, the high risk of thrombosis, and cost.²⁴⁵

Other

Seizure: If a seizure occurs during SA, the abortion should be discontinued.²⁵⁹ Initial treatment includes maintaining the patient's airway, monitoring vital signs, administering IV fluids, and oxygen.^{245,259} The majority of seizures will resolve spontaneously.^{245,259} Treatment options for seizure lasting greater than 5 minutes or repetitive seizures include IM midazolam 10 mg single dose if no IV access, IV midazolam 2–5 mg, or IV diazepam 0.15–0.2 mg/kg/dose to a maximum of 10 mg/dose and may repeat dose once.²⁶⁰ Transfer to the nearest hospital should be done if SA was performed in an outpatient setting.²⁵⁹

Asthma exacerbation: Approximately 8% of women seeking IA report current use of asthma medication.²⁴⁵ Women with well-controlled asthma can undergo usual SA but should be advised to use their asthma medication the day of the procedure and to bring their inhalers.²⁵⁹ A delay in the procedure may be considered if a woman's asthma symptoms require continuous steroid therapy or if she has current acute symptoms, frequent exacerbations, or a recent attack requiring medical treatment.²⁴⁵ If an asthma exacerbation occurs (mostly in relation to NSAID sensitivity), observation in a monitored setting and oxygen administration to maintain oxygen saturation of at least 90% must be done.^{245,261} If there is no response, consider oral systemic corticosteroids,^{261,262} and organize transfer to the nearest hospital.

Vasovagal syncope: A vasovagal reaction can be precipitated by stress, pain, venipuncture, PCB, or cervical dilation.²⁴⁵ The woman may experience hypotension and, rarely, bradycardia.²⁴⁵ She should remain supine with legs elevated. All instruments should be removed from the vagina and cervix. Most episodes resolve without treatment.²⁴⁵ For prolonged or severe incidents, consider treatment with atropine 0.5 mg IV in addition to hydration, antiemetics, and airway support.²⁴⁵

Recommendations

30. Each facility where abortions are performed should have easily available written emergency protocols (Strong recommendation. Level of evidence: Very low).
31. Every facility where abortions are performed should engage in regular emergency drills (Strong recommendation. Level of evidence: Very low).

Complications of second trimester MA

Uterine rupture: Uterine rupture is a rare complication of labour induction.^{263,264} It was reported with scarred and unscarred uterus and with urea/PGF_{2α},²⁶⁵ oxytocin,²⁶⁶ MISO,^{267–272} and MIFE-MISO.^{273,274}

The incidence of rupture with the use MISO was 0.4% (2 of 461) with 1 prior low-transverse CS, 0% (0 of 46) with 2 prior low-transverse CS, and 50% (1 of 2) with a prior classical CS in 1 review,²⁷⁵ and it was 0.28% (2 of 722) in women with a prior CS in another review,²⁷⁶ compared with 0.04% (1 of 2834) in women without a prior CS.²⁷⁶ In 1 prospective study²⁷⁷ and several retrospective studies and case series,^{278–291} uterine rupture was observed with scarred uterus in some studies^{283,285–287,290} and not in others.^{277–282,284,288,289} Uterine rupture happened at any GA, with any MISO dosage, and, in some cases, with oxytocin.²⁹¹

Recommendation

19. The use of misoprostol for second trimester medical abortion is safe after 1 prior low-transverse Caesarean section. There is insufficient evidence regarding its use in women with 2 or more prior Caesarean sections or a prior classical Caesarean section (Weak recommendation. Level of evidence: Very low).

Severe bleeding: In women undergoing MA, the incidence of hemorrhage requiring transfusion is between 0.7% and 3.0%.^{209,292–294} One recent study reported a higher incidence of blood transfusion of 6% in 2008/2010 and 4% in 2014.²⁹⁵ Retained POC is the most common cause.¹⁶⁶ MIFE-MISO might be associated with less blood loss.¹⁶⁶ Comparative studies of second trimester MA versus SA found either less severe bleeding with SA^{294,296} or no difference.^{293,296,297}

Late Complications

Infection

The incidence of infection requiring antibiotics after first and second trimester SA has been reported to be 0.01% to 2.44% and 0.8% to 1.6%, respectively.³⁶ Rates are more difficult to measure with second trimester MA due to prostaglandin-induced pyrexia.³⁶ Some report that the difference in infection rate is not significant between second trimester SA and MA,²⁹⁶ while others find it higher for second trimester MA.³⁶ Typical symptoms of infection start within a few days and include fever ($\geq 38^{\circ}\text{C}$), chills, increased pelvic pain, and foul-smelling discharge or prolonged bleeding. Findings also include uterine tenderness and possibly an elevated white blood cell count. Treatment includes broad-spectrum antibiotics and antipyretics and, in case of severe infection, hospitalization, debridement, and IV antibiotics. Retained POC should be aspirated to eliminate a nidus of infection.^{40,41,245} There is no evidence that abstaining from sexual intercourse after SA or MA reduces post-abortion infection.

Retained products of conception

Symptoms of retained POC commonly include vaginal bleeding, abdominal pain, and signs of infection.⁴¹ Routine ultrasonography following IA to exclude retained products is not recommended. Appropriate treatment includes vacuum aspiration or MISO.⁴¹

First trimester SA: Retained POC is uncommon (0.7% to 4%) following vacuum aspiration by a skilled provider.^{41,128} Sharp curettage does not decrease the risk of retained POC.⁴¹ Inspection of the POC immediately after SA is recommended, and, if incomplete, imaging and reaspiration are indicated.^{3,41}

Second trimester IA: Retained POC are more common following second trimester MA than SA. In 1 RCT on 18 women,²⁵⁰ 4 of 9 women in the MA group required a vacuum aspiration: 3 for retained placenta and 1 for delayed presentation of retained POC. One case series of D&E between 13 and 26 weeks¹⁷³ and another case series with MIFE-MISO between 13 and 21 weeks²⁰⁹ showed retained POC in 0.3% of D&E versus 7% of MIFE-MISO MA. The initial method failed in 0.2% of D&E versus 3% of MIFE-MISO MA at 24 hours and 1% at 36 hours.²⁰⁹ Experts recommend that, for second trimester MA, 4 hours should be allowed following fetal expulsion for the expulsion of the placenta if the woman is stable. If bleeding is heavy or if the placenta does not deliver, vacuum aspiration with a large cannula (14–16 mm) can be used. If the placenta is sitting in the cervix, attempt extraction with sponge forceps. Immediate inspection of the placenta is always necessary.

Failed abortion and continuing pregnancy

SA includes a 0.1% risk of failure.¹²⁸ A study of 33 090 SAs using suction curettage up to 12 weeks reported a 0.23% failure rate.¹³³ The risk was increased with SA performed prior to 6 weeks of gestation, in multiparous women, and women with uterine anomalies.¹²⁸ Failed abortion is usually recognized by immediate POC examination.¹² In case of an ongoing pregnancy, women might fail to have a period within 4–8 weeks after abortion and complain of continuing symptoms and signs of pregnancy. A uterine evacuation procedure should be offered.⁴¹

Recommendation

32. If women fail to have a period within 8 weeks following induced abortion and/or complain of continuing symptoms and signs of pregnancy, a new or ongoing pregnancy should be suspected and repeat procedure offered (Strong recommendation. Level of evidence: Very low).

Follow-Up

Routine FU after IA is not required but may be recommended to confirm complete abortion, discuss or reinforce contraception, and diagnose complications.²⁹⁸ Women who are referred for abortion following a diagnosis of fetal anomaly should be offered a follow-up appointment once the abortion is complete. A systematic review concluded that routine FU after SA is unnecessary when examination of POC confirms a complete abortion and contraceptive needs have been met.²⁹⁹ All women should be informed about signs and symptoms (Table 4) that should trigger a visit, and those who wish to have FU care should be offered an appointment.

Recommendation

35. Women referred for abortion from a fetal diagnosis clinic should be offered follow-up to review any additional information obtained from the abortion and provide support (Strong recommendation. Level of evidence: Low).

Future Reproductive Outcomes

Many studies on long-term sequelae of SA are either case-control or retrospective cohort studies where choice of control groups is critical. Ideally, controls should be recruited from the same population as cases or exposed women and have had a IA in the most recent pregnancy.³⁰⁰

Asherman syndrome

Asherman syndrome (intrauterine adhesions) is a rare complication linked to direct and/or indirect trauma of the endometrium, and it can occur following delivery, miscarriage, or SA.^{301–305} Gentle surgical techniques, use of vacuum aspiration (MVA or EVA), and limiting sharp curettage are advised.^{41,151,306} Adhesion formation in the presence of retained POC may be more likely after CS than after SA or vaginal birth; curettage postpartum may lead to the most severe adhesions.^{303,305} Management of the adhesions (hysteroscopic resection) has a reasonable success rate to restore fertility when desired.^{303,305,307–310}

Subfertility

Studies on the risk of subsequent fertility impairment are limited to small cohort studies, case-control studies and case reports, many of which employing outdated techniques.^{311–322} Reviews do not find evidence of association between SA and subsequent subfertility, but highlight methodologic problems and call for high-quality large prospective cohort studies.^{315,317} Two notable, but rare, exceptions relate to: (1) midtrimester SA complicated by a retained fetal bone fragment; and (2) SA complicated by intrauterine adhesions.^{310,313,315,323,324}

Ectopic pregnancy

Most large case-control studies with adequate control groups and control of confounding factors have found no association between 1 or more SAs and further risk of EP.^{325–334} Significant associations between SA and subsequent EP were observed in studies with small numbers of EP cases, those that failed to control for important risk factors or chose inadequate control groups, and those conducted in countries where abortion was illegal and complicated by infection or retained POC.^{311,332,335–338}

Miscarriage

The majority of large case-control or retrospective cohort studies with adequate control groups and control of confounding factors confirmed no association between 1 or more induced SAs and the risk of miscarriage in a subsequent pregnancy.^{332,338–346} A dose-response effect was not demonstrated.^{339,343,345,347} However, 1 large cohort study³⁴⁶ showed an increased risk of miscarriage when women became pregnant within again less than 3 months of a first trimester IA (OR 4.06; 95% CI 1.98–8.31) regardless of abortion method. Significant associations between induced SA and subsequent miscarriage were observed in studies that failed to control for important risk factors or chose inadequate control groups.^{332,347,348} In addition, an association between miscarriage and IA via dilation and sharp curettage has been described.³³²

Placenta previa

Most large case-control or retrospective cohort studies with adequate control groups and control of confounding factors confirm absence of association between 1 or more SAs and subsequent abnormal placentation, especially PP.^{171,349–360} Similar findings are reported in women obtaining MA.^{360–362} Significant associations between induced SA and placental abnormalities were observed in studies with small samples, inadequate control for risk factors or inadequate control groups, and those that were conducted in countries where abortion was illegal, complicated by infection or performed with sharp curettage.^{338,358,363–367} With respect to causal relationship, sharp curettage may result in uterine scarring and subsequent faulty placentation.

Preterm birth

Two meta-analyses^{368,369} and several large case-control or retrospective cohort studies with various control groups and control of some confounding factors found an association between 1 or more surgical IAs and an increased risk of subsequent PTB.^{317,332,338,370–378} PTB risk increased with the number of previous surgical SAs.^{368,369,371–374} However, several cohort studies with adequate control groups and control for important confounders,^{327,379–383} as well as several smaller studies with various methodological flaws,^{359,365,384–387} did not demonstrate an association between 1 or more induced SAs and the risk of PTB in the next further pregnancy. Many studies did not differentiate between spontaneous and induced PTB, which may confound the results.³¹⁶

Low birth weight

The majority of well-designed case-control or retrospective cohort studies reported no association between 1 or more surgical IAs and risk of subsequent

LBW.^{339,345,359,363,365,373,376,379,380,386,388–390} However, a 2009 meta-analysis³⁶⁸ found a slight increased risk of subsequent LBW following IA (OR 1.35; 95% CI 1.20–1.52) but no increased risk of SGA. LBW risk increased with the number of IAs.³⁶⁸ One review article³³² found no significant increased risk of LBW in the pregnancy after IA via vacuum aspiration, but did find an increase association with second trimester SA. In addition, significant associations between IA and subsequent LBW infants were observed in 3 studies that failed to distinguish MA versus SA, chose inadequate control groups, or failed to control for important risk factors.^{391–393}

Summary Statements

13. An abundant amount of evidence provides reassurance concerning future reproductive outcomes following induced abortion (Level of evidence: Low).
14. Sharp curettage during induced abortion appears associated with the development of uterine adhesions, risk of miscarriage, placenta previa, and subfertility (Level of evidence: Low).

Recommendation

33. Sharp curettage is not recommended in replacement for vacuum aspiration (Strong recommendation. Level of evidence: Low), nor should routine sharp curettage be performed during induced abortion (Weak recommendation. Level of evidence: Low).

Contraception Post-Abortion

Ovulation can occur as early as 8–10 days after an abortion, with a mean between 21 and 29 days after SA.^{394–397} More than 80% of women ovulate within 1 month of IA, with estrogen and progesterone levels returning to near normal levels within 1 week.^{394,397} Thus, if contraception is desired, it should be initiated promptly. Moderate-quality evidence indicates that same-day access to contraception and abortion leads to fewer subsequent abortions and births at 12 to 24 months and is associated with an increased likelihood of using a highly effective method.^{398–400}

Intrauterine contraception

In the absence of method contraindications^{401–403} or complications of IA, immediate insertion of a levonorgestrel intrauterine system or a copper IUD may be performed. Moderate-level evidence indicates that immediate IUCD insertion post SA is safe^{45,400,404,405} and does not carry an increased risk of perforation, infection, or discontinuation.^{45,405–408} Expulsion rates may be higher for immediate insertion compared with delayed insertion, but not all studies found the difference to be significant.^{45,400,404,409}

An increase in expulsion rate was noted when insertion occurred after second trimester SA compared with first trimester SA,^{45,48,404–407} but the difference was not significant in all studies and should not preclude immediate IUCD placement immediately after a second trimester IA.

RCTs have demonstrated that immediate IUCD placement at time of both trimester SA is associated with higher IUCD use at 6 months^{45,48,49} and statistically significant reductions in repeat pregnancies compared with delayed placement,^{48,49,399,410} likely due to lower likelihood of women returning for interval insertion.^{48,49,399,410} One prospective cohort study⁴¹¹ and 1 RCT⁴⁰⁸ demonstrated a significant decrease in repeat abortions at 24 months after IUCD insertion compared with initiation of other contraceptive methods (6.5% vs. 14.5%; $P < 0.001$)⁴¹¹ or oral contraceptives (1.4% vs 5.6%; $P = 0.003$).⁴⁰⁸

No backup contraception is required if the IUCD is inserted immediately. If initiation is delayed more than 7 days post-abortion, backup or abstinence is required for 7 days after levonorgestrel intrauterine system insertion (no backup is required following copper IUD insertion).⁴⁰²

Hormonal contraception

In the absence of contraindications, hormonal contraception can be initiated immediately after IA.⁴⁰³

CHC: CHC (COC, patch, and ring) can be initiated immediately after first trimester SA.^{402,403} Although evidence is available, CHC may be started after a second trimester IA once completed. Immediate COC start after SA is not associated with an increase in vaginal bleeding, side effects, or clinically significant changes in coagulation parameters compared with delayed initiation or other non-hormonal contraceptive methods.^{412,413} Limited evidence on vaginal contraceptive ring used immediately post first trimester IA has demonstrated no increase in infection or other adverse events at 3 months.⁴¹⁴ One RCT of immediate contraceptive patch initiation found no adverse effect on post-abortion bleeding and no improvement in method continuation at 6 months.⁴¹⁵

If CHC is started immediately, no backup contraception is required. If CHC is not started immediately, backup contraception or abstinence should be used until initiation of CHC and for the first 7 days of CHC use.

Progestin-only contraception: The progestin-only pill and DMPA can be started immediately after IA.^{402,403} Women who choose DMPA have lower repeat pregnancy rates at 12–24 months compared with those who choose COC.^{408,410} If not started immediately, backup contraception or abstinence

should be used until initiation of the method and for the first 48 hours of POP use or first 7 days following DMPA administration.

Other reversible contraceptives methods

Condoms and spermicides can be used as soon as intercourse resumes.^{416,417} There is no optimal timing for use of the cervical cap or diaphragm after SA; it is suggested that the diaphragm and cap should not be used until 6 weeks after a second trimester IA.⁴⁰³ Natural family planning methods should not be used until menstrual cycles have resumed. Women who have had a failure of their contraceptive method, who are relying on less effective methods, or who have difficulty with adherence should also be counselled about the use of EC.⁴¹⁷ Advance provision of EC is safe, increases the likelihood of EC use,⁴¹⁸ and should be considered for all post-abortion patients.⁴¹⁹

Permanent contraception

Tubal ligation can safely be performed laparoscopically at the time of first and second trimester SA.^{420–422} The risk of pregnancy following immediate tubal ligation is lower compared with women who delay their procedure.⁴²¹

Recommendation

34. Contraception should be started as soon as possible after the abortion (Strong recommendation. Level of evidence: High).

CONCLUSION

One third of Canadian women will undergo abortion in their lifetime, and IA is among the commonly performed procedures in Canada and globally. While IA is very safe, evidence-based best practices are associated with fewer complications, improved ease, and increased satisfaction for patients and providers.

REFERENCES

1. Induced abortions reported in Canada in 2015. Ottawa: Canadian Institute for Health Information; 2017. Available at: <https://www.cihi.ca/sites/default/files/document/induced-abortion-can-2015-en-web.xlsx>. Accessed on May 1, 2017.
2. Costescu D, Guilbert E, Bernardin J, et al. Medical abortion. *J Obstet Gynaecol Can* 2016;38:366–89.
3. National Abortion Federation. 2017 clinical policy guidelines for abortion care. Washington, DC: National Abortion Federation; 2017. Available at: www.prochoice.org. Accessed on January 4, 2018.
4. Norman WV, Guilbert ER, Okpaleke C, et al. Abortion health services in Canada: results of a 2012 national survey. *Can Fam Physician* 2016;62:e209–17.

5. Barnard S, Kim C, Park MH, et al. Doctors or mid-level providers for abortion. *Cochrane Database Syst Rev* 2015;(7):CD011242.
6. Warriner IK, Meirik O, Hoffman M, et al. Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and mid-level providers in South Africa and Vietnam: a randomised controlled equivalence trial. *Lancet* 2006;368:1965–72.
7. Freedman MA, Jillson DA, Coffin RR, et al. Comparison of complication rates in first trimester abortions performed by physician assistants and physicians. *Am J Public Health* 1986;76:550–4.
8. Goldman MB, Occhiuto JS, Peterson LE, et al. Physician assistants as providers of surgically induced abortion services. *Am J Public Health* 2004;94:1352–7.
9. Jejeebhoy SJ, Kalyanwala S, Zavier AJ, et al. Can nurses perform manual vacuum aspiration (MVA) as safely and effectively as physicians? Evidence from India. *Contraception* 2011;84:615–21.
10. Weitz TA, Taylor D, Desai S, et al. Safety of aspiration abortion performed by nurse practitioners, certified nurse midwives, and physician assistants under a California legal waiver. *Am J Public Health* 2013;103:454–61.
11. Davis A, Easterling T. Medical evaluation and management. In: Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009. p. 78–89.
12. Meckstroth K, Paul M. First-trimester aspiration abortion. In: Paul M, Lichtenberg S, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: 2009.
13. Lederle L, Steinauer JE, Montgomery A, et al. Obesity as a risk factor for complications after second-trimester abortion by dilation and evacuation. *Obstet Gynecol* 2015;126:585–92.
14. Murphy LA, Thornburg LL, Glantz JC, et al. Complications of surgical termination of second-trimester pregnancy in obese versus nonobese women. *Contraception* 2012;86:402–6.
15. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002;96:1004–17.
16. American Society of Anesthesiologists. ASA physical status classification system. American Society of Anesthesiologists; 2014. Available at: <https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system>. Accessed on August 16, 2017.
17. Marchiano D, Thomas A, Lapinski R, et al. Intraoperative blood loss and gestational age at pregnancy termination. *Prim Care Update Ob Gyns* 1998;5:204–5.
18. Guiahi M, Schiller G, Sheeder J, et al. Safety of first-trimester uterine evacuation in the outpatient setting for women with common chronic conditions. *Contraception* 2015;92:453–7.
19. Wiebe ER, Byczko B, Kaczorowski J, et al. Can we safely avoid fasting before abortions with low-dose procedural sedation? A retrospective cohort chart review of anesthesia-related complications in 47,748 abortions. *Contraception* 2013;87:51–4.
20. Wilson LC, Chen BA, Creinin MD. Low-dose fentanyl and midazolam in outpatient surgical abortion up to 18 weeks of gestation. *Contraception* 2009;79:122–8.
21. Kulier R, Kapp N. Comprehensive analysis of the use of pre-procedure ultrasound for first- and second-trimester abortion. *Contraception* 2011;83:30–3.
22. Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. *J Ultrasound Med* 1989;8:71–5.
23. Prager SW, Oyer DJ. Second-trimester surgical abortion. *Clin Obstet Gynecol* 2009;52:179–87.
24. Perriera LK, Arslan AA, Masch R. Placenta praevia and the risk of adverse outcomes during second trimester abortion: a retrospective cohort study. *Aust N Z J Obstet Gynaecol* 2017;57:99–104.
25. Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. *Obstet Gynecol* 2004;103:729–37.
26. Boonstra H, Benson Gold R, Richards CL, Finer LB. *Abortion in women's lives*. New York: Guttmacher Institute; 2006.
27. Ferris LE, McMain-Klein M, Colodny N, et al. Factors associated with immediate abortion complications. *CMAJ* 1996;154:1677–85.
28. Jatlaoui TC, Ewing A, Mandel MG, et al. Abortion surveillance – United States, 2013. *MMWR Surveill Summ* 2016;65:1–44.
29. Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. *Reprod Health Matters* 2008;16(Suppl):173–82.
30. Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. *Obstet Gynecol* 2012;119:215–9.
31. Heisterberg L, Hebjørn S, Andersen LF, et al. Sequelae of induced first-trimester abortion: a prospective study assessing the role of postabortal pelvic inflammatory disease and prophylactic antibiotics. *Am J Obstet Gynecol* 1986;155:76–80.
32. Sawaya GF, Grady D, Kerlikowske K, et al. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. *Obstet Gynecol* 1996;87:884–90.
33. Low N, Mueller M, Van Vliet HA, et al. Perioperative antibiotics to prevent infection after first-trimester abortion. *Cochrane Database Syst Rev* 2012;(3):CD005217.
34. Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. *Br J Obstet Gynaecol* 1998;105:599–604.
35. Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. *BJOG* 2004;111:982–8.
36. Achilles SL, Reeves MF. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. *Contraception* 2011;83:295–309.
37. Lichtenberg ES, Shott S. A randomized clinical trial of prophylaxis for vacuum abortion: 3 versus 7 days of doxycycline. *Obstet Gynecol* 2003;101:726–31.
38. Caruso S, Di Mari L, Cacciatore A, et al. [Antibiotic prophylaxis with prulifloxacin in women undergoing induced abortion: a randomized controlled trial]. *Minerva Ginecol* 2008;60:1–5.
39. Reeves MF, Lohr PA, Hayes JL, et al. Doxycycline serum levels at the time of dilation and evacuation with two dosing regimens. *Contraception* 2009;79:129–33.
40. Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion. Evidence-based clinical guideline number 7. London: Royal College of Obstetricians and Gynaecologists; 2011. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/abortion-guideline_web_1.pdf. Accessed on January 4, 2018.

41. World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva: World Health Organization; 2012. p. 1–134.
42. Zhu JL, Zhang WH, Cheng Y, et al. Impact of post-abortion family planning services on contraceptive use and abortion rate among young women in China: a cluster randomised trial. *Eur J Contracept Reprod Health Care* 2009;14:46–54.
43. Carneiro Gomes Ferreira AL, Impieri SA, Evangelista PR, et al. The effectiveness of contraceptive counseling for women in the postabortion period: an intervention study. *Contraception* 2011;84:377–83.
44. Bender SS, Geirsson RT. Effectiveness of preabortion counseling on postabortion contraceptive use. *Contraception* 2004;69:481–7.
45. Bednarek PH, Creinin MD, Reeves MF, et al. Immediate versus delayed IUD insertion after uterine aspiration. *N Engl J Med* 2011;364:2208–17.
46. Cameron ST, Glasier A, Chen ZE, et al. Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. *BJOG* 2012;119:1074–80.
47. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, et al. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. *Reprod Health* 2016;13:42.
48. Hohmann HL, Reeves MF, Chen BA, et al. Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. *Contraception* 2012;85:240–5.
49. Cremer M, Bullard KA, Mosley RM, et al. Immediate vs. delayed post-abortion copper T 380A IUD insertion in cases over 12 weeks of gestation. *Contraception* 2011;83:522–7.
50. Suprpto K, Reed S. Naproxen sodium for pain relief in first-trimester abortion. *Am J Obstet Gynecol* 1984;150:1000–1.
51. Wiebe ER, Rawling M. Pain control in abortion. *Int J Gynaecol Obstet* 1995;50:41–6.
52. Li CFI, Wong CYG, Chan CPB, et al. A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. *Contraception* 2003;67:101–5.
53. Romero I, Turok D, Gilliam M. A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. *Contraception* 2008;77:56–9.
54. Jakobsson J, Rane K, Davidson S. Intramuscular NSAIDs reduce post-operative pain after minor outpatient anaesthesia. *Eur J Anaesthesiol* 1996;13:67–71.
55. Heath PJ, Ogg TW. Prophylactic analgesia for daycase termination of pregnancy: a double-blind study with controlled release dihydrocodeine. *Anaesthesia* 1989;44:991–4.
56. Dahl V, Fjellanger F, Raeder JC. No effect of preoperative paracetamol and codeine suppositories for pain after termination of pregnancies in general anaesthesia. *Eur J Pain* 2000;4:211–5.
57. Cade L, Ashley J. Prophylactic paracetamol for analgesia after vaginal termination of pregnancy. *Anaesth Intensive Care* 1993;21:93–6.
58. Roche NE, Li D, James D, et al. The effect of perioperative ketorolac on pain control in pregnancy termination. *Contraception* 2012;85:299–303.
59. Wiebe ER. Comparison of the efficacy of different local anesthetics and techniques of local anesthesia in therapeutic abortions. *Am J Obstet Gynecol* 1992;167:131–4.
60. Wiebe E, Podhradsky L, Dijk V. The effect of lorazepam on pain and anxiety in abortion. *Contraception* 2003;67:219–21.
61. Goldberg AB, Drey EA, Whitaker AK, et al. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. *Obstet Gynecol* 2005;106:234–41.
62. Bartz D, Maurer R, Allen RH, et al. Buccal misoprostol compared with synthetic osmotic cervical dilator before surgical abortion: a randomized controlled trial. *Obstet Gynecol* 2013;122:57–63.
63. Edelman AB, Buckmaster JG, Goetsch MF, et al. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. *Am J Obstet Gynecol* 2006;194:425–30.
64. Drey EA, Benson LS, Sokoloff A, et al. Buccal misoprostol plus laminaria for cervical preparation before dilation and evacuation at 21–23 weeks of gestation: a randomized controlled trial. *Contraception* 2014;89:307–13.
65. Goldberg AB, Fortin JA, Drey EA, et al. Cervical preparation before dilation and evacuation using adjunctive misoprostol or mifepristone compared with overnight osmotic dilators alone: a randomized controlled trial. *Obstet Gynecol* 2015;126:599–609.
66. Boraas CM, Achilles SL, Cremer ML, et al. Synthetic osmotic dilators with adjunctive misoprostol for same-day dilation and evacuation: a randomized controlled trial. *Contraception* 2016;94:467–72.
67. Saxena P, Salhan S, Sarda N. Sublingual versus vaginal route of misoprostol for cervical ripening prior to surgical termination of first trimester abortions. *Eur J Obstet Gynecol Reprod Biol* 2006;125:109–13.
68. Okanlomo KA, Ngotho D, Moodley J. Effect of misoprostol for cervical ripening prior to pregnancy interruption before twelve weeks of gestation. *East Afr Med J* 1999;76:552–5.
69. Renner RM, Nichols MD, Jensen JT, et al. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. *Obstet Gynecol* 2012;119:1030–7.
70. Renner RM, Edelman AB, Nichols MD, et al. Refining paracervical block techniques for pain control in first trimester surgical abortion: a randomized controlled noninferiority trial. *Contraception* 2016;94:461–6.
71. Renner RM, Jensen JT, Nichols MD, et al. Pain control in first trimester surgical abortion. *Cochrane Database Syst Rev* 2009;(2):CD006712.
72. Mankowski JL, Kingston J, Moran T, et al. Paracervical compared with intracervical lidocaine for suction curettage: a randomized controlled trial. *Obstet Gynecol* 2009;113:1052–7.
73. Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. *Obstet Gynecol* 1990;76:129–35.
74. Grimes DA, Cates W. Deaths from paracervical anesthesia used for first-trimester abortion, 1972–1975. *N Engl J Med* 1976;295:1397–9.
75. Berger GS, Tyler CW, Harrod EK. Maternal deaths associated with paracervical block anesthesia. *Am J Obstet Gynecol* 1974;118:1142–3.
76. Wells N. Management of pain during abortion. *J Adv Nurs* 1989;14:56–62.
77. Rawling MJ, Wiebe ER. A randomized controlled trial of fentanyl for abortion pain. *Am J Obstet Gynecol* 2001;185:103–7.
78. Allen RH, Fitzmaurice G, Lifford KL, et al. Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial. *Obstet Gynecol* 2009;113:276–83.

79. Agostini A, Maruani J, Roblin P, et al. A double-blind, randomized controlled trial of the use of a 50:50 mixture of nitrous oxide/oxygen in legal abortions. *Contraception* 2012;86:79–83.
80. Kan ASY, Caves N, Wong SYW, et al. A double-blind, randomized controlled trial on the use of a 50:50 mixture of nitrous oxide/oxygen in pain relief during suction evacuation for the first trimester pregnancy termination. *Hum Reprod* 2006;21:2606–11.
81. Bonnardot JP, Mailliet M, Brulé ML, et al. [Ambulatory anesthesia and induced abortion. Comparative study of propofol-alfentanil and ketamine-midazolam combinations]. *Ann Fr Anesth Reanim* 1987;6:297–300.
82. Jakobsson J, Oddby E, Rane K. Patient evaluation of four different combinations of intravenous anaesthetics for short outpatient procedures. *Anaesthesia* 1993;48:1005–7.
83. Raeder JC. Propofol anaesthesia versus paracervical blockade with alfentanil and midazolam sedation for outpatient abortion. *Acta Anaesthesiol Scand* 1992;36:31–7.
84. Lazenby GB, Fogelson NS, Aeby T. Impact of paracervical block on postabortion pain in patients undergoing abortion under general anesthesia. *Contraception* 2009;80:578–82.
85. Shapiro AG, Cohen H. Auxiliary pain relief during suction curettage. *Contraception* 1975;11:25–30.
86. Wu J, Chaplin W, Amico J, et al. Music for surgical abortion care study: a randomized controlled pilot study. *Contraception* 2012;85:496–502.
87. Marc I, Rainville P, Masse B, et al. Hypnotic analgesia intervention during first-trimester pregnancy termination: an open randomized trial. *Am J Obstet Gynecol* 2008;199:469, e1–9.
88. Marc I, Rainville P, Verreault R, et al. The use of hypnosis to improve pain management during voluntary interruption of pregnancy: an open randomized preliminary study. *Contraception* 2007;75:52–8.
89. Castro C, Tharmaratnam U, Brockhurst N, et al. Patient-controlled analgesia with fentanyl provides effective analgesia for second trimester labour: a randomized controlled study. *Can J Anaesth* 2003;50:1039–46.
90. Fiala C, Swahn ML, Stephansson O, et al. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks gestation. *Hum Reprod* 2005;20:3072–7.
91. Rosenblatt WH, Cioffi AM, Sinatra R, et al. Metoclopramide: an analgesic adjunct to patient-controlled analgesia. *Anesth Analg* 1991;73:553–5.
92. Winkler M, Wolters S, Funk A, et al. [Does para-cervical block offer additional advantages in abortion induction with gemeprost in the 2nd trimester?]. *Zentralbl Gynakol* 1997;119:621–4.
93. Andersson IM, Benson L, Christensson K, et al. Paracervical block as pain treatment during second-trimester medical termination of pregnancy: an RCT with bupivacaine versus sodium chloride. *Hum Reprod* 2016;31:67–74.
94. Grimes DA, Stuart GS, Raymond EG. Feticidal digoxin injection before dilation and evacuation abortion: evidence and ethics. *Contraception* 2012;85:140–3.
95. Isada NB, Pryde PG, Johnson MP, et al. Fetal intracardiac potassium chloride injection to avoid the hopeless resuscitation of an abnormal abortus: I. Clinical issues. *Obstet Gynecol* 1992;80:296–9.
96. Gill P, Cyr D, Afrakhtah M, et al. Induction of fetal demise in advanced pregnancy terminations: report on a funic potassium chloride protocol. *Fetal Diagn Ther* 1994;9:278–82.
97. Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. *Obstet Gynecol* 1999;94:139–41.
98. Li Kim Mui SV, Chitrit Y, Boulanger MC, et al. Sepsis due to *Clostridium perfringens* after pregnancy termination with feticide by cordocentesis: a case report. *Fetal Diagn Ther* 2002;17:124–6.
99. Coke GA, Baschat AA, Mighty HE, et al. Maternal cardiac arrest associated with attempted fetal injection of potassium chloride. *Int J Obstet Anesth* 2004;13:287–90.
100. Pasquini L, Pontello V, Kumar S. Intracardiac injection of potassium chloride as method for feticide: experience from a single UK tertiary centre. *BJOG* 2008;115:528–31.
101. Silva LV, Cecatti JG, Pinto e Silva JL, et al. Feticide does not modify duration of labor induction in cases of medical termination of pregnancy. *Fetal Diagn Ther* 2008;23:192–7.
102. Borrás A, Gómez O, Sanz M, et al. Feticide followed by mifepristone-misoprostol regimen for midtrimester termination of pregnancy in two cases of complete placenta previa. *Fetal Diagn Ther* 2010;28:114–6.
103. Sfakianaki AK, Davis KJ, Copel JA, et al. Potassium chloride-induced fetal demise: a retrospective cohort study of efficacy and safety. *J Ultrasound Med* 2014;33:337–41.
104. Bhide A, Sairam S, Hollis B, et al. Comparison of feticide carried out by cordocentesis versus cardiac puncture. *Ultrasound Obstet Gynecol* 2002;20:230–2.
105. Hern WM, Zen C, Ferguson KA, et al. Outpatient abortion for fetal anomaly and fetal death from 15–34 menstrual weeks' gestation: techniques and clinical management. *Obstet Gynecol* 1993;81:301–6.
106. Hern WM. Laminaria, induced fetal demise and misoprostol in late abortion. *Int J Gynaecol Obstet* 2001;75:279–86.
107. Borgatta L, Betstadt SJ, Reed A, et al. Relationship of intraamniotic digoxin to fetal demise. *Contraception* 2010;81:328–30.
108. Drey EA, Thomas LJ, Benowitz NL, et al. Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. *Am J Obstet Gynecol* 2000;182:1063–6.
109. Jackson RA, Teplin VL, Drey EA, et al. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. *Obstet Gynecol* 2001;97:471–6.
110. Molaei M, Jones HE, Weisberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. *Contraception* 2008;77:223–5.
111. Nucatola D, Roth N, Gatter M. A randomized pilot study on the effectiveness and side-effect profiles of two doses of digoxin as fetocide when administered intraamniotically or intrafetally prior to second-trimester surgical abortion. *Contraception* 2010;81:67–74.
112. Steward R, Melamed A, Kim R, et al. Infection and extramural delivery with use of digoxin as a feticidal agent. *Contraception* 2012;85:150–4.
113. Singh S, Seligman NS, Jackson B, et al. Fetal intracardiac potassium chloride injection to expedite second-trimester dilation and evacuation. *Fetal Diagn Ther* 2012;31:63–8.
114. Dean G, Colarossi L, Lunde B, et al. Safety of digoxin for fetal demise before second-trimester abortion by dilation and evacuation. *Contraception* 2012;85:144–9.
115. Garipey AM, Chen BA, Hohmann HL, et al. Transvaginal administration of intraamniotic digoxin prior to dilation and evacuation. *Contraception* 2013;87:76–80.

116. Garg M, Markovchick N. Hyperkalemic paralysis: an elective abortion gone wrong. *J Emerg Med* 2013;45:190–3.
117. Roncari D, Politch JA, Sonalkar S, et al. Inflammation or infection at the time of second trimester induced abortion. *Contraception* 2013;87:67–70.
118. Tocce K, Sheeder JL, Edwards LJ, et al. Feasibility, effectiveness and safety of transvaginal digoxin administration prior to dilation and evacuation. *Contraception* 2013;88:706–11.
119. Batra P, Sridhar A, Kim C, et al. Transabdominal versus transvaginal digoxin administration prior to second-trimester abortion: interim analysis of a randomized pilot study of patient preference. *Contraception* 2014;90:301.
120. White KO, Nucata DL, Westhoff C. Intra-fetal compared with intra-amniotic digoxin before dilation and evacuation: a randomized controlled trial. *Obstet Gynecol* 2016;128:1071–6.
121. Senat MV, Fischer C, Bernard JP, et al. The use of lidocaine for fetocide in late termination of pregnancy. *BJOG* 2003;110:296–300.
122. López-Cepero R, Lynch L, de la Vega A. Effectiveness and safety of lidocaine in the induction of fetal cardiac asystole for second trimester pregnancy termination. *Bol Asoc Med P R* 2013;105:14–7.
123. Tocce K, Leach KK, Sheeder JL, et al. Umbilical cord transection to induce fetal demise prior to second-trimester D&E abortion. *Contraception* 2013;88:712–6.
124. Grimes D, Schulz K, Cates WJ, et al. The Joint Program for the Study of Abortion/CDC: a preliminary report. In: Hern WM, Andrikopoulos B, editors. *Abortion in the seventies*. New York: National Abortion Federation; 1977. p. 41–6.
125. Dommergues M, Cahen F, Garel M, et al. Feticide during second- and third-trimester termination of pregnancy: opinions of health care professionals. *Fetal Diagn Ther* 2003;18:91–7.
126. Du Passage A, Le Ray C, Grangé G, et al. [Termination of pregnancy and placenta previa, interest of performing feticide before the labor induction?]. *J Gynecol Obstet Biol Reprod (Paris)* 2011;40:149–55.
127. Ruano R, Dumez Y, Cabrol D, et al. Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa – does feticide decrease postdelivery maternal hemorrhage? *Fetal Diagn Ther* 2004;19:475–8.
128. Lichtenberg ES, Paul M, Society of Family Planning. Surgical abortion prior to 7 weeks of gestation. *Contraception* 2013;88:7–17.
129. Kara F, Dogan NU, Bati S, et al. Early surgical abortion: safe and effective. *Eur J Contracept Reprod Health Care* 2013;18:120–6.
130. Goldberg AB, Dean G, Kang MS, et al. Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. *Obstet Gynecol* 2004;103:101–7.
131. Mittal S, Sehgal R, Aggarwal S, et al. Cervical priming with misoprostol before manual vacuum aspiration versus electric vacuum aspiration for first-trimester surgical abortion. *Int J Gynaecol Obstet* 2011;112:34–9.
132. Burnhill MS, Edelman DA, Armstead JW. The relationship between gestational age and the weight of the products of conception. *Adv Plan Parent* 1978;13:9–13.
133. Kaunitz AM, Rovira EZ, Grimes DA, et al. Abortions that fail. *Obstet Gynecol* 1985;66:533–7.
134. Fielding WL, Lee SY, Friedman EA. Continued pregnancy after failed first trimester abortion. *Obstet Gynecol* 1978;52:56–8.
135. Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation. *Am J Obstet Gynecol* 1997;176:1101–6.
136. Edward J, Creinin MD. Early abortion: surgical and medical options. *Current Problems in Obstetrics, Gynecology and Fertility* 1997;20(1):6–32.
137. Paul ME, Mitchell CM, Rogers AJ, et al. Early surgical abortion: efficacy and safety. *Am J Obstet Gynecol* 2002;187:407–11.
138. Mechstroth K, Paul M. First-trimester aspiration abortion. In: Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009. p. 135–56.
139. Bélanger E, Melzack R, Lauzon P. Pain of first-trimester abortion: a study of psychosocial and medical predictors. *Pain* 1989;36:339–50.
140. Borgatta L, Nickinovich D. Pain during early abortion. *J Reprod Med* 1997;42:287–93.
141. Canadian Institute for Health Information. Induced abortion quick stats, 2013. Ottawa: Canadian Institute for Health Information; 2015. Available at: https://www.cihi.ca/sites/default/files/document/induced_abortion_can_2013_en_web.xlsx. Accessed on February 14, 2018.
142. Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. *Obstet Gynecol* 2015;125:175–83.
143. Zane S, Creanga AA, Berg CJ, et al. Abortion-related mortality in the United States: 1998–2010. *Obstet Gynecol* 2015;126:258–65.
144. Creanga AA, Syverson C, Seed K, et al. Pregnancy-related mortality in the United States, 2011–2013. *Obstet Gynecol* 2017;130:366–73.
145. ACOG practice bulletin no. 135: second-trimester abortion. *Obstet Gynecol* 2013;121:1394–406.
146. Caddy S, Yudin MH, Hakim J, et al. Best practices to minimize risk of infection with intrauterine device insertion. *J Obstet Gynaecol Can* 2014;36:266–76.
147. World Health Organization. *Clinical practice handbook for safe abortion*. Geneva: World Health Organization; 2014.
148. Racek CM, Chen BA, Creinin MD. Complication rates and utility of intravenous access for surgical abortion procedures from 12 to 18 weeks of gestation. *Contraception* 2010;82:286–90.
149. O'Connell K, Jones HE, Simon M, et al. First-trimester surgical abortion practices: a survey of National Abortion Federation members. *Contraception* 2009;79:385–92.
150. Varli IH, Lindelius A, Bergström M. Is preoperative vaginal cleansing necessary for control of infection after first trimester vacuum curettage? *Acta Obstet Gynecol Scand* 2005;84:650–3.
151. Royal College of Obstetricians and Gynaecologists. Best practice in comprehensive abortion care. Guideline paper #2. Royal College of Obstetricians and Gynaecologists; 2015. Available at: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/bpp2/>. Accessed on May 14, 2017.
152. Allen RH, Goldberg AB. Cervical dilation before first-trimester surgical abortion (<14 weeks' gestation). *Contraception* 2016;93:277–91.
153. Hulka JF, Lefler HT, Anglone A, et al. A new electronic force monitor to measure factors influencing cervical dilation for vacuum curettage. *Am J Obstet Gynecol* 1974;120:166–73.

154. International Federation of Gynecology and Obstetrics (FIGO). Consensus statement on uterine evacuation: uterine evacuation: use of vacuum aspiration or medications, not sharp curettage. FIGO; 2011. Available at: <http://www.figo.org/sites/default/files/FIGO%20DC%20Statement.pdf>. Accessed on October 17, 2017.
155. Gilman Barber AR, Rhone SA, Fluker MR. Curettage and Asherman's syndrome: lessons to (re-) learn? *J Obstet Gynaecol Can* 2014;36:997–1001.
156. Kaneshiro B, Bednarek P, Isley M, et al. Blood loss at the time of first-trimester surgical abortion in anticoagulated women. *Contraception* 2011;83:431–5.
157. Pentlicky S, Harken T, Schreiber CA. Controversies in family planning: first trimester uterine evacuation for the anticoagulated patient. *Contraception* 2012;85:434–6.
158. Kapp N, Lohr PA, Ngo TD, et al. Cervical preparation for first trimester surgical abortion. *Cochrane Database Syst Rev* 2010;(2):CD007207.
159. Webber K, Grivell RM. Cervical ripening before first trimester surgical evacuation for non-viable pregnancy. *Cochrane Database Syst Rev* 2015;(11):CD009954.
160. Promsonthi P, Preechapornprasert A, Chanrachakul B. Nitric oxide donors for cervical ripening in first-trimester surgical abortion. *Cochrane Database Syst Rev* 2015;(2):CD007444.
161. Ganer Herman H, Kerner R, Gluck O, et al. Different routes of misoprostol for cervical priming in first trimester surgical abortions: a randomized blind trial. *Arch Gynecol Obstet* 2017;295:943–50.
162. Ercan CM, Coksuer H, Karasahin KE, et al. Comparison of different preoperative sublingual misoprostol regimens for surgical termination of first trimester pregnancies: a prospective randomized trial. *J Reprod Med* 2011;56:247–53.
163. Punjyashthira A, Pongrojapw D, Suwannarurk K, et al. The effectiveness of sublingual or oral administration of misoprostol for cervical ripening before manual vacuum aspiration in first trimester termination of pregnancy: randomized controlled trial. *J Med Assoc Thai* 2014;97:1009–15.
164. Meirik O, My Huong NT, Piaggio G, et al. Complications of first-trimester abortion by vacuum aspiration after cervical preparation with and without misoprostol: a multicentre randomised trial. *Lancet* 2012;379:1817–24.
165. Hendricks C. Physiology. In: Berger GS, Brenner WE, Keith LG, editors. *Second-trimester abortion: perspectives after a decade of experience*. Boston: John Wright PSG; 1981.
166. Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP guideline #20131. *Contraception* 2013;87:331–42.
167. Schulz KF, Grimes DA, Christensen DD. Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. *Lancet* 1985;2:353–6.
168. Crawford JT, Edelman AB, Pereira L, et al. The effects of vasopressin injection on uterine artery blood flow during dilation and evacuation. *Am J Obstet Gynecol* 2007;196:e38–9.
169. Martin JD, Shenk LG. Intraoperative myocardial infarction after paracervical vasopressin infiltration. *Anesth Analg* 1994;79:1201–2.
170. Alexander GD, Brown M. A safe dose of vasopressin for paracervical infiltration. *Anesth Analg* 1995;81:428.
171. Schneider D, Halperin R, Langer R, et al. Abortion at 18–22 weeks by laminaria dilation and evacuation. *Obstet Gynecol* 1996;88:412–4.
172. Newmann SJ, Dalve-Endres A, Diedrich JT, et al. Cervical preparation for second trimester dilation and evacuation. *Cochrane Database Syst Rev* 2010;(8):CD007310.
173. Peterson WF, Berry FN, Grace MR, et al. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. *Obstet Gynecol* 1983;62:185–90.
174. Fox MC, Krajewski CM. Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation: SFP guideline #2013–4. *Contraception* 2014;89:75–84.
175. Todd CS, Soler M, Castleman L, et al. Buccal misoprostol as cervical preparation for second trimester pregnancy termination. *Contraception* 2002;65:415–8.
176. Ramesh S, Roston A, Zimmerman L, et al. Misoprostol 1 to 3 h preprocedure vs. overnight osmotic dilators prior to early second-trimester surgical abortion. *Contraception* 2015;92:234–40.
177. Grossman D, Constant D, Lince-Deroche N, et al. A randomized trial of misoprostol versus laminaria before dilation and evacuation in South Africa. *Contraception* 2014;90:234–41.
178. Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. *Contraception* 2006;73:420–30.
179. Borgatta L, Roncari D, Sonalkar S, et al. Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14–16 weeks: a randomized trial. *Contraception* 2012;86:567–71.
180. Ohannessian A, Baumstarck K, Maruani J, et al. Mifepristone and misoprostol for cervical ripening in surgical abortion between 12 and 14 weeks of gestation: a randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol* 2016;201:151–5.
181. Sagiv R, Mizrahi Y, Glickman H, et al. Laminaria vs. vaginal misoprostol for cervical preparation before second-trimester surgical abortion: a randomized clinical trial. *Contraception* 2015;91:406–11.
182. Carbonell JL, Gallego FG, Llorente MP, et al. Vaginal vs. sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial. *Contraception* 2007;75:230–7.
183. Paris A, Sonalkar S, Kattan D, et al. Mifepristone and misoprostol compared with osmotic dilator insertion before surgical abortion at 15–18 weeks. *Obstet Gynecol* 2014;123(5 Suppl).
184. Casey FE, Ye PP, Perritt JD, et al. A randomized controlled trial evaluating same-day mifepristone and misoprostol compared to misoprostol alone for cervical preparation prior to second-trimester surgical abortion. *Contraception* 2016;94:127–33.
185. Shaw KA, Shaw JG, Hugin M, et al. Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial. *Contraception* 2015;91:313–9.
186. World Health Organization. *Frequently asked clinical questions about medical abortion*. Geneva: World Health Organization; 2006.
187. Weeks A, Fiala C. *Misoprostol.org: Safe usage guide for obstetrics and gynaecology*. Available at: <http://www.misoprostol.org/dosage-guidelines/>. Accessed on October 1, 2017.
188. Tu YA, Chen CL, Lai YL, et al. Transcervical double-balloon catheter as an alternative and salvage method for medical termination of pregnancy in midtrimester. *Taiwan J Obstet Gynecol* 2017;56:77–80.
189. Toptas T, Mendilcioglu I, Simsek M, et al. Intravaginal misoprostol alone versus intravaginal misoprostol and extraamniotic Foley catheter for second trimester pregnancy termination: an observational study. *Ginekol Pol* 2014;85:577–81.

190. Velipasoglu M, Ozdemir CY, Ozek B, et al. Sequential use of Foley catheter with misoprostol for second trimester pregnancy termination in women with and without caesarean scars: a prospective cohort study. *J Matern Fetal Neonatal Med* 2018;31:677–81.
191. Rezk MA, Sanad Z, Dawood R, et al. Comparison of intravaginal misoprostol and intracervical Foley catheter alone or in combination for termination of second trimester pregnancy. *J Matern Fetal Neonatal Med* 2015;28:93–6.
192. Bani-Irshaid I, Athamneh TZ, Bani-Khaled D, et al. Termination of second and early third trimester pregnancy: comparison of 3 methods. *East Mediterr Health J* 2006;12:605–9.
193. Thornburg LL, Grace D, Gray AL, et al. Placement of laminaria tents does not improve time to delivery in patients undergoing second trimester labor induction with misoprostol. *J Matern Fetal Neonatal Med* 2010;23:928–31.
194. Almog B, Levin I, Winkler N, et al. The contribution of laminaria placement for cervical ripening in second trimester termination of pregnancy induced by intra-amniotic injection of prostaglandin F(2)alpha followed by concentrated oxytocin infusion. *Eur J Obstet Gynecol Reprod Biol* 2005;118:32–5.
195. Mazouni C, Vejux N, Menard JP, et al. Cervical preparation with laminaria tents improves induction-to-delivery interval in second- and third-trimester medical termination of pregnancy. *Contraception* 2009;80:101–4.
196. Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. *Contraception* 2005;72:358–61.
197. Jain JK, Mishell DR. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. *Am J Obstet Gynecol* 1996;175:173–7.
198. Prairie BA, Lauria MR, Kapp N, et al. Mifepristone versus laminaria: a randomized controlled trial of cervical ripening in midtrimester termination. *Contraception* 2007;76:383–8.
199. Atlas RO, Lemus J, Reed J, et al. Second trimester abortion using prostaglandin E2 suppositories with or without intracervical Laminaria japonica: a randomized study. *Obstet Gynecol* 1998;92:398–402.
200. Moreno-Ruiz NL, Vesona JL, Betstadt SJ, et al. Misoprostol priming prior to second trimester medical abortion. *Int J Gynaecol Obstet* 2009;106:67–8.
201. Saha S, Bal R, Ghosh S, et al. Medical abortion in late second trimester: a comparative study with misoprostol through vaginal versus oral followed by vaginal route. *J Indian Med Assoc* 2006;104:81–2, 84.
202. Wong KS, Ngai CS, Chan KS, et al. Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double-blind placebo-controlled trial. *Contraception* 1996;54:23–5.
203. Mousiolis A, Sindos M, Papantoniou N, et al. Can isosorbide mononitrate be useful in second trimester termination of pregnancies? *Contraception* 2013;88:41–4.
204. Li CI, Chan CC, Ho P. A study of the efficacy of cervical ripening with nitric oxide donor versus placebo for cervical priming before second-trimester termination of pregnancy. *Contraception* 2003;68:269–72.
205. Akkenapally PL. A comparative study of misoprostol only and mifepristone plus misoprostol in second trimester termination of pregnancy. *J Obstet Gynaecol India* 2016;66(Suppl 1):251–7.
206. Dabash R, Chelli H, Hajri S, et al. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14–21 weeks of pregnancy. *Int J Gynaecol Obstet* 2015;130:40–4.
207. Ngoc NT, Shochet T, Raghavan S, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. *Obstet Gynecol* 2011;118:601–8.
208. Ben-Meir A, Erez Y, Feigenberg T, et al. Mifepristone followed by high-dose oxytocin drip for second-trimester abortion: a randomized, double-blind, placebo-controlled, pilot study. *J Reprod Med* 2009;54:511–6.
209. Ashok PW, Templeton A, Wagaarachchi PT, et al. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. *Contraception* 2004;69:51–8.
210. Ho PC, Tsang SS, Ma HK. Reducing the induction to abortion interval in termination of second trimester pregnancies: a comparison of mifepristone with laminaria tent. *Br J Obstet Gynaecol* 1995;102:648–51.
211. Chai J, Tang OS, Hong QQ, et al. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion. *Hum Reprod* 2009;24:320–4.
212. Abbas DF, Blum J, Ngoc NT, et al. Simultaneous administration compared with a 24-hour mifepristone-misoprostol interval in second-trimester abortion: a randomized controlled trial. *Obstet Gynecol* 2016;128:1077–83.
213. Sharp A, Navaratnam K, Abreu P, et al. Short versus standard mifepristone and misoprostol regimen for second- and third-trimester termination of pregnancy for fetal anomaly. *Fetal Diagn Ther* 2016;39:140–6.
214. Heikinheimo O, Suhonen S, Haukkamaa M. One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. *Reprod Biomed Online* 2004;8:236–9.
215. Chaudhuri P, Mandal A, Das C, et al. Dosing interval of 24 hours versus 48 hours between mifepristone and misoprostol administration for mid-trimester termination of pregnancy. *Int J Gynaecol Obstet* 2014;124:134–8.
216. Nilas L, Glavind-Kristensen M, Vejborg T, et al. One or two day mifepristone-misoprostol interval for second trimester abortion. *Acta Obstet Gynecol Scand* 2007;86:1117–21.
217. Hou S, Chen Q, Zhang L, et al. Mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy: a prospective, open-label, randomized clinical trial. *Eur J Obstet Gynecol Reprod Biol* 2010;151:149–53.
218. Mentula M, Suhonen S, Heikinheimo O. One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy: a randomized trial. *Hum Reprod* 2011;26:2690–7.
219. Di Carlo C, Savoia F, Morra I, et al. Effects of a prolonged, 72 hours, interval between mifepristone and gemeprost in second trimester termination of pregnancy: a retrospective analysis. *Gynecol Endocrinol* 2014;30:605–7.
220. Nakayama D, Masuzaki H, Miura K, et al. Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost. *Contraception* 2007;75:238–40.
221. Breeze AC, Lees CC, Kumar A, et al. Palliative care for prenatally diagnosed lethal fetal abnormality. *Arch Dis Child Fetal Neonatal Ed* 2007;92:F56–8.
222. Guidelines for health care professionals supporting families experiencing a perinatal loss. *Paediatr Child Health* 2001;6:469–90.

223. Joseph KS, Basso M, Davies C, et al. Rationale and recommendations for improving definitions, registration requirements and procedures related to fetal death and stillbirth. *BJOG* 2017;124:1153–7.

224. Fulcheri E, di Capua E, Ragni N. Histologic examination of products of conception at the time of pregnancy termination. *Int J Gynaecol Obstet* 2003;80:315–6.

225. Prasad CJ, Ireland KM. The effectiveness of cytologic evaluation of products of conception. *Arch Pathol Lab Med* 1992;116:1159–62.

226. Heath V, Chadwick V, Cooke I, et al. Should tissue from pregnancy termination and uterine evacuation routinely be examined histologically? *BJOG* 2000;107:727–30.

227. Paul M, Lackie E, Mitchell C, et al. Is pathology examination useful after early surgical abortion? *Obstet Gynecol* 2002;99:567–71.

228. Seckl MJ, Gillmore R, Foskett M, et al. Routine terminations of pregnancy – should we screen for gestational trophoblastic neoplasia? *Lancet* 2004;364:705–7.

229. Yuen BH, Callegari PB. Occurrence of molar pregnancy in patients undergoing elective abortion: comparison with other clinical presentations. *Am J Obstet Gynecol* 1986;154:273–6.

230. Munsick RA. Clinical test for placenta in 300 consecutive menstrual aspirations. *Obstet Gynecol* 1982;60:738–41.

231. Felding C, Mikkelsen AL, Villerslev L. First-trimester legally induced abortions: the amount of aspirated tissue in relation to gestational age. *Arch Gynecol Obstet* 1991;249:149–51.

232. Hammond C, Chasen S. Dilation and evacuation. In: Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009. p. 157–77.

233. Mercer BM, Sklar S, Shariatmadar A, et al. Fetal foot length as a predictor of gestational age. *Am J Obstet Gynecol* 1987;156:350–5.

234. Drey EA, Kang MS, McFarland W, et al. Improving the accuracy of fetal foot length to confirm gestational duration. *Obstet Gynecol* 2005;105:773–8.

235. Yonke N, Leeman LM. First-trimester surgical abortion technique. *Obstet Gynecol Clin North Am* 2013;40:647–70.

236. Aldrete score sheet/table, definition. Available at: <https://www.easycalculation.com/medical/learn-alldrete-score.php>. Accessed on November 8, 2017.

237. Goldstein S, Reeves M. Assessment and ultrasound in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009. p. 67–9.

238. Steier JA, Bergsjø P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. *Obstet Gynecol* 1984;64:391–4.

239. Espey E, MacIsaac L. Contraception and surgical abortion aftercare. In: Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009. p. 211.

240. Sit D, Rothschild AJ, Creinin MD, et al. Psychiatric outcomes following medical and surgical abortion. *Hum Reprod* 2007;22:878–84.

241. Cohen S. Abortion and mental health: myths and realities. *Guttmacher Policy Rev* 2006;9:2–7.

242. Rees DI, Sabia JJ. The relationship between abortion and depression: new evidence from the fragile families and child wellbeing study. *Med Sci Monit* 2007;13:CR430–6.

243. Broen AN, Moum T, Bødtker AS, et al. Predictors of anxiety and depression following pregnancy termination: a longitudinal five-year follow-up study. *Acta Obstet Gynecol Scand* 2006;85:317–23.

244. Taylor D, Upadhyay UD, Fjerstad M, et al. Standardizing the classification of abortion incidents: the Procedural Abortion Incident Reporting and Surveillance (PAIRS) Framework. *Contraception* 2017;96:1–13.

245. Paul M, Lichtenberg ES, Borgatta L, et al., editors. *Management of unintended and abnormal pregnancy: comprehensive abortion care*. Oxford, UK: Wiley-Blackwell; 2009.

246. Allen RH, Goldberg AB, Board of Society of Family Planning. *Cervical dilation before first-trimester surgical abortion (<14 weeks' gestation)*. SFP guideline 20071. *Contraception* 2007;76:139–56.

247. Steinauer JE, Diedrich JT, Wilson MW, et al. Uterine artery embolization in postabortion hemorrhage. *Obstet Gynecol* 2008;111:881–9.

248. Hamilton Health Sciences protocol on management of haemorrhage. Hamilton, Ontario, Canada: McMaster University Hospital Centre; 2017.

249. Cooper JM, Brady RM. Intraoperative and early postoperative complications of operative hysteroscopy. *Obstet Gynecol Clin North Am* 2000;27:347–66.

250. Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial. *BJOG* 2004;111:148–53.

251. Darney PD, Atkinson E, Hirabayashi K. Uterine perforation during second-trimester abortion by cervical dilation and instrumental extraction: a review of 15 cases. *Obstet Gynecol* 1990;75:441–4.

252. Stubblefield PG, Borgatta L. Complications after induced abortion. In: Pearlman MD, Tintinalli JE, Dyne PL, editors. *Emergency care, diagnosis and management*. New York: McGraw-Hill; 2004. p. 65–86.

253. White K, Carroll E, Grossman D. Complications from first-trimester aspiration abortion: a systematic review of the literature. *Contraception* 2015;92:422–38.

254. Sherer DM, Salame G, Shah T, et al. Transvaginal sonography of postabortal (Redo) syndrome. *J Clin Ultrasound* 2011;39:155–6.

255. Borten M, Friedman EA. Drainage of postabortion hematometra by Foley catheter. *Am J Obstet Gynecol* 1984;149:908–9.

256. Lurie S, Feinstein M, Mamet Y. Disseminated intravascular coagulopathy in pregnancy: thorough comprehension of etiology and management reduces obstetricians' stress. *Arch Gynecol Obstet* 2000;263:126–30.

257. York S, Lichtenberg ES. Characteristics of presumptive idiopathic disseminated intravascular coagulation during second-trimester induced abortion. *Contraception* 2012;85:489–95.

258. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol* 1995;172:1158–67, discussion 1167–9.

259. Guiahi M, Davis A, Society of Family Planning. First-trimester abortion in women with medical conditions: release date October 2012 SFP guideline #20122. *Contraception* 2012;86:622–30.

260. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report

- of the Guideline Committee of the American Epilepsy Society. *Epilepsy Curr* 2016;16:48–61.
261. Camargo CA, Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. *Proc Am Thorac Soc* 2009;6:357–66.
 262. Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. *Am Fam Physician* 2011;84:40–7.
 263. Zwart JJ, Richters JM, Ory F, et al. Uterine rupture in the Netherlands: a nationwide population-based cohort study. *BJOG* 2009;116:1069–78, discussion 1078–80.
 264. Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. *Contraception* 2011;84:4–18.
 265. Atienza MF, Burkman RT, King TM. Midtrimester abortion induced by hyperosmolar urea and prostaglandin F2 alpha in patients with previous Caesarean section: clinical course and potential for uterine rupture. *Am J Obstet Gynecol* 1980;138:55–9.
 266. Chapman SJ, Crispens M, Owen J, et al. Complications of midtrimester pregnancy termination: the effect of prior Caesarean delivery. *Am J Obstet Gynecol* 1996;175:889–92.
 267. Al-Hussaini TK. Uterine rupture in second trimester abortion in a grand multiparous woman: a complication of misoprostol and oxytocin. *Eur J Obstet Gynecol Reprod Biol* 2001;96:218–9.
 268. Letourneur B, Parant O, Tofani V, et al. [Uterine rupture on unscarred uterus following labor induction for 2(nd) trimester termination of pregnancy with oral misoprostol: conservative management]. *J Gynecol Obstet Biol Reprod (Paris)* 2002;31:371–3.
 269. Nayki U, Taner CE, Mizrak T, et al. Uterine rupture during second trimester abortion with misoprostol. *Fetal Diagn Ther* 2005;20:469–71.
 270. Chen M, Shih JC, Chiu WT, et al. Separation of Caesarean scar during second-trimester intravaginal misoprostol abortion. *Obstet Gynecol* 1999;94:840.
 271. Berghahn L, Christensen D, Droste S. Uterine rupture during second-trimester abortion associated with misoprostol. *Obstet Gynecol* 2001;98:976–7.
 272. Jwarah E, Greenhalf JO. Rupture of the uterus after 800 micrograms misoprostol given vaginally for termination of pregnancy. *BJOG* 2000;107:807.
 273. Phillips K, Berry C, Mathers AM. Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. *Eur J Obstet Gynecol Reprod Biol* 1996;65:175–6.
 274. Bagga R, Chaudhary N, Kalra J. Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol. *Int J Gynaecol Obstet* 2004;87:42–3.
 275. Berghella V, Airoidi J, O'Neill AM, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. *BJOG* 2009;116:1151–7.
 276. Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after Caesarean delivery: a systematic review. *Obstet Gynecol* 2009;113:1117–23.
 277. Herabutya Y, Chanarachakul B, Punyavachira P. Induction of labor with vaginal misoprostol for second trimester termination of pregnancy in the scarred uterus. *Int J Gynaecol Obstet* 2003;83:293–7.
 278. Rouzi AA. Second-trimester pregnancy termination with misoprostol in women with previous Caesarean sections. *Int J Gynaecol Obstet* 2003;80:317–8.
 279. Pongsatha S, Tongsong T. Misoprostol for second trimester termination of pregnancies with prior low transverse Caesarean section. *Int J Gynaecol Obstet* 2003;80:61–2.
 280. Tarim E, Kilicdag E, Bagis T, et al. Second-trimester pregnancy termination with oral misoprostol in women who have had one Caesarean section. *Int J Gynaecol Obstet* 2005;90:84–5.
 281. Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior Caesarean delivery. *Obstet Gynecol* 2005;105:352–6.
 282. Daskalakis GJ, Mesogitis SA, Papanitiou NE, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. *BJOG* 2005;112:97–9.
 283. Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous Caesarean section. *Contraception* 2006;73:244–8.
 284. Bhattacharjee N, Ganguly RP, Saha SP. Misoprostol for termination of mid-trimester post-Caesarean pregnancy. *Aust N Z J Obstet Gynaecol* 2007;47:23–5.
 285. Esteve JL, Gallego FG, Llorente MP, et al. Late second-trimester abortions induced with mifepristone, misoprostol and oxytocin: a report of 428 consecutive cases. *Contraception* 2008;78:52–60.
 286. Küçüköz Güleç U, Urunsak IF, Eser E, et al. Misoprostol for midtrimester termination of pregnancy in women with 1 or more prior Caesarean deliveries. *Int J Gynaecol Obstet* 2013;120:85–7.
 287. Aslan H, Unlu E, Agar M, et al. Uterine rupture associated with misoprostol labor induction in women with previous Caesarean delivery. *Eur J Obstet Gynecol Reprod Biol* 2004;113:45–8.
 288. Daponte A, Nzewenga G, Dimopoulos KD, et al. The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single Caesarean section. *Contraception* 2006;74:324–7.
 289. Naguib AH, Morsi HM, Borg TF, et al. Vaginal misoprostol for second-trimester pregnancy termination after one previous Caesarean delivery. *Int J Gynaecol Obstet* 2010;108:48–51.
 290. Cayrac M, Faillie JL, Flandrin A, et al. Second- and third-trimester management of medical termination of pregnancy and fetal death in utero after prior caesarean section. *Eur J Obstet Gynecol Reprod Biol* 2011;157:145–9.
 291. Clouqueur E, Coulon C, Vaast P, et al. [Use of misoprostol for induction of labor in case of fetal death or termination of pregnancy during second or third trimester of pregnancy: efficiency, dosage, route of administration, side effects, use in case of uterine scar]. *J Gynecol Obstet Biol Reprod (Paris)* 2014;43:146–61.
 292. Rose SB, Shand C, Simmons A. Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases. *Aust N Z J Obstet Gynaecol* 2006;46:479–85.
 293. Mauelshagen A, Sadler LC, Roberts H, et al. Audit of short term outcomes of surgical and medical second trimester termination of pregnancy. *Reprod Health* 2009;6:16.
 294. Grossman D, Constant D, Lince N, et al. Surgical and medical second trimester abortion in South Africa: a cross-sectional study. *BMC Health Serv Res* 2011;11:224.
 295. Constant D, Harries J, Malaba T, et al. Clinical outcomes and women's experiences before and after the introduction of mifepristone into second-trimester medical abortion services in South Africa. *PLoS ONE* 2016;11:e0161843.

296. Autry AM, Hayes EC, Jacobson GF, et al. A comparison of medical induction and dilation and evacuation for second-trimester abortion. *Am J Obstet Gynecol* 2002;187:393–7.
297. Whitley KA, Trinchere K, Prutsman W, et al. Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes. *Am J Obstet Gynecol* 2011;205:386, e1–7.
298. Keder LM. Best practices in surgical abortion. *Am J Obstet Gynecol* 2003;189:418–22.
299. Grossman D, Ellertson C, Grimes DA, et al. Routine follow-up visits after first-trimester induced abortion. *Obstet Gynecol* 2004;103:738–45.
300. Atrash HK, Strauss LT, Kendrick JS, et al. The relation between induced abortion and ectopic pregnancy. *Obstet Gynecol* 1997;89:512–8.
301. Asherman J. The influence of artificial abortion on fertility. *Harefuah* 1952;43:27–9.
302. Yu D, Wong YM, Cheong Y, et al. Asherman syndrome – one century later. *Fertil Steril* 2008;89:759–79.
303. Dawood A, Al-Talib A, Tulandi T. Predisposing factors and treatment outcome of different stages of intrauterine adhesions. *J Obstet Gynaecol Can* 2010;32:767–70.
304. Kjer JJ. Asherman syndrome in a Danish population. *Acta Obstet Gynecol Scand* 2014;93:425–7.
305. Barel O, Krakov A, Pansky M, et al. Intrauterine adhesions after hysteroscopic treatment for retained products of conception: what are the risk factors? *Fertil Steril* 2015;103:775–9.
306. Gilman AR, Dewar KM, Rhone SA, et al. Intrauterine adhesions following miscarriage: look and learn. *J Obstet Gynaecol Can* 2016;38:453–7.
307. Sanders B. Uterine factors and infertility. *J Reprod Med* 2006;51:169–76.
308. Hamerlynck TW, Blikkendaal MD, Schoot BC, et al. An alternative approach for removal of placental remnants: hysteroscopic morcellation. *J Minim Invasive Gynecol* 2013;20:796–802.
309. Bougie O, Lortie K, Shenassa H, et al. Treatment of Asherman's syndrome in an outpatient hysteroscopy setting. *J Minim Invasive Gynecol* 2015;22:446–50.
310. Xiao S, Wan Y, Xue M, et al. Etiology, treatment, and reproductive prognosis of women with moderate-to-severe intrauterine adhesions. *Int J Gynaecol Obstet* 2014;125:121–4.
311. Parazzini F, Ferraroni M, Tozzi L, et al. Induced abortions and risk of ectopic pregnancy. *Hum Reprod* 1995;10:1841–4.
312. Howie FL, Henshaw RC, Naji SA, et al. Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. *Br J Obstet Gynaecol* 1997;104:829–33.
313. Moon HS, Park YH, Kwon HY, et al. Iatrogenic secondary infertility caused by residual intrauterine fetal bone after midtrimester abortion. *Am J Obstet Gynecol* 1997;176:369–70.
314. Torres-Sánchez L, López-Carrillo L, Espinoza H, et al. Is induced abortion a contributing factor to tubal infertility in Mexico? Evidence from a case-control study. *BJOG* 2004;111:1254–60.
315. Lanzarone VF, Pardey JM. Retained intrauterine fetal bone as a rare cause of secondary infertility. *Aust N Z J Obstet Gynaecol* 2009;49:700–1.
316. Lowit A, Bhattacharya S, Bhattacharya S. Obstetric performance following an induced abortion. *Best Pract Res Clin Obstet Gynaecol* 2010;24:667–82.
317. Thorp JM, Hartmann KE, Shadigian E. Long-term physical and psychological health consequences of induced abortion: review of the evidence. *Obstet Gynecol Surv* 2003;58:67–79.
318. Hemminki E, Klemetti R, Sevon T, et al. Induced abortions previous to IVF: an epidemiologic register-based study from Finland. *Hum Reprod* 2008;23:1320–3.
319. Verhoeve HR, Steures P, Flierman PA, et al. History of induced abortion and the risk of tubal pathology. *Reprod Biomed Online* 2008;16:304–7.
320. Hassan MA, Killick SR. Is previous aberrant reproductive outcome predictive of subsequently reduced fecundity? *Hum Reprod* 2005;20:657–64.
321. Zhou W, Olsen J. Are complications after an induced abortion associated with reproductive failures in a subsequent pregnancy? *Acta Obstet Gynecol Scand* 2003;82:177–81.
322. Melcer Y, Smorgick N, Schneider D, et al. Comparison of reproductive outcomes following retained products of conception after vaginal delivery versus first-trimester abortion. *Gynecol Obstet Invest* 2015;80:206–10.
323. Elford K, Claman P. Novel treatment of a patient with secondary infertility due to retained fetal bone. *Fertil Steril* 2003;79:1028–30.
324. Goldberg JM, Roberts S. Restoration of fertility after hysteroscopic removal of intrauterine bone fragments. *Obstet Gynecol* 2008;112:470–2.
325. Levin AA, Schoenbaum SC, Stubblefield PG, et al. Ectopic pregnancy and prior induced abortion. *Am J Public Health* 1982;72:253–6.
326. Daling JR, Chow WH, Weiss NS, et al. Ectopic pregnancy in relation to previous induced abortion. *JAMA* 1985;253:1005–8.
327. Frank PI, Kay CR, Lewis TL, et al. Outcome of pregnancy following induced abortion. Report from the joint study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists. *Br J Obstet Gynaecol* 1985;92:308–16.
328. Thorburn J, Berntsson C, Philipson M, et al. Background factors of ectopic pregnancy. I. Frequency distribution in a case-control study. *Eur J Obstet Gynecol Reprod Biol* 1986;23:321–31.
329. Thorburn J, Philipson M, Lindblom B. Background factors of ectopic pregnancy. II. Risk estimation by means of a logistic model. *Eur J Obstet Gynecol Reprod Biol* 1986;23:333–40.
330. Burkman RT, Mason KJ, Gold EB. Ectopic pregnancy and prior induced abortion. *Contraception* 1988;37:21–7.
331. Holt VL, Daling JR, Voigt LF, et al. Induced abortion and the risk of subsequent ectopic pregnancy. *Am J Public Health* 1989;79:1234–8.
332. Atrash HK, Hogue CJ. The effect of pregnancy termination on future reproduction. *Baillieres Clin Obstet Gynaecol* 1990;4:391–405.
333. Skjeldestad FE, Atrash HK. Evaluation of induced abortion as a risk factor for ectopic pregnancy: a case-control study. *Acta Obstet Gynecol Scand* 1997;76:151–8.
334. Skjeldestad FE, Gargiullo PM, Kendrick JS. Multiple induced abortions as risk factor for ectopic pregnancy: a prospective study. *Acta Obstet Gynecol Scand* 1997;76:691–6.
335. Orhue AA, Unuigbo JA, Ogbuide WE. The contribution of previous induced abortion to tubal ectopic pregnancy. *West Afr J Med* 1989;8:257–63.

336. Tharaux-Deneux C, Bouyer J, Job-Spira N, et al. Risk of ectopic pregnancy and previous induced abortion. *Am J Public Health* 1998;88:401–5.
337. Bouyer J, Coste J, Shojaei T, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. *Am J Epidemiol* 2003;157:185–94.
338. Bhattacharya S, Lowit A, Bhattacharya S, et al. Reproductive outcomes following induced abortion: a national register-based cohort study in Scotland. *BMJ Open* 2012;2:e000911.
339. Bracken MB, Bryce-Buchanan C, Srisuphan W, et al. Risk of late first and second trimester miscarriage after induced abortion. *Am J Perinatol* 1986;3:84–91.
340. Coste J, Job-Spira N, Fernandez H. Risk factors for spontaneous abortion: a case-control study in France. *Hum Reprod* 1991;6:1332–7.
341. Frank PI, McNamee R, Hannaford PC, et al. The effect of induced abortion on subsequent pregnancy outcome. *Br J Obstet Gynaecol* 1991;98:1015–24.
342. Hogue CJ, Cates W, Tietze C. Impact of vacuum aspiration abortion on future childbearing: a review. *Fam Plann Perspect* 1983;15:119–26.
343. Kline J, Stein Z, Susser M, et al. Induced abortion and the chromosomal characteristics of subsequent miscarriages (spontaneous abortions). *Am J Epidemiol* 1986;123:1066–79.
344. Obel EB. Risk of spontaneous abortion following legally induced abortion. *Acta Obstet Gynecol Scand* 1980;59:131–5.
345. Parazzini F, Chatenoud L, Tozzi L, et al. Induced abortion in the first trimester of pregnancy and risk of miscarriage. *Br J Obstet Gynaecol* 1998;105:418–21.
346. Zhou W, Olsen J, Nielsen GL, et al. Risk of spontaneous abortion following induced abortion is only increased with short interpregnancy interval. *J Obstet Gynaecol* 2000;20:49–54.
347. Infante-Rivard C, Gauthier R. Induced abortion as a risk factor for subsequent fetal loss. *Epidemiology* 1996;7:540–2.
348. Sun Y, Che Y, Gao E, et al. Induced abortion and risk of subsequent miscarriage. *Int J Epidemiol* 2003;32:449–54.
349. Grimes DA, Techman T. Legal abortion and placenta previa. *Am J Obstet Gynecol* 1984;149:501–4.
350. Hogue CJ, Cates W, Tietze C. The effects of induced abortion on subsequent reproduction. *Epidemiol Rev* 1982;4:66–94.
351. Rose GL, Chapman MG. Aetiological factors in placenta praevia – a case controlled study. *Br J Obstet Gynaecol* 1986;93:586–8.
352. Tangtrakul S, Thongjerm M, Suthutvoravuth S, et al. Outcome of delivery following first-pregnancy abortion. *J Med Assoc Thai* 1988;71(Suppl 1):68–71.
353. Williams MA, Mittendorf R, Lieberman E, et al. Cigarette smoking during pregnancy in relation to placenta previa. *Am J Obstet Gynecol* 1991;165:28–32.
354. Taylor VM, Kramer MD, Vaughan TL, et al. Placental previa in relation to induced and spontaneous abortion: a population-based study. *Obstet Gynecol* 1993;82:88–91.
355. Ananth CV, Smulian JC, Vintzileos AM. The association of placenta previa with history of Caesarean delivery and abortion: a metaanalysis. *Am J Obstet Gynecol* 1997;177:1071–8.
356. Zhou W, Nielsen GL, Larsen H, et al. Induced abortion and placenta complications in the subsequent pregnancy. *Acta Obstet Gynecol Scand* 2001;80:1115–20.
357. Kalish RB, Chasen ST, Rosenzweig LB, et al. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. *Am J Obstet Gynecol* 2002;187:882–5.
358. Johnson LG, Mueller BA, Daling JR. The relationship of placenta previa and history of induced abortion. *Int J Gynaecol Obstet* 2003;81:191–8.
359. Jackson JE, Grobman WA, Haney E, et al. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. *Int J Gynaecol Obstet* 2007;96:12–5.
360. Gan C, Zou Y, Wu S, et al. The influence of medical abortion compared with surgical abortion on subsequent pregnancy outcome. *Int J Gynaecol Obstet* 2008;101:231–8.
361. Zhu QX, Gao ES, Chen AM, et al. Mifepristone-induced abortion and placental complications in subsequent pregnancy. *Hum Reprod* 2009;24:315–9.
362. Männistö J, Mentula M, Bloigu A, et al. Medical termination of pregnancy during the second versus the first trimester and its effects on subsequent pregnancy. *Contraception* 2014;89:109–15.
363. Obel E. Pregnancy complications following legally induced abortion with special reference to abortion technique. *Acta Obstet Gynecol Scand* 1979;58:147–52.
364. Barrett JM, Boehm FH, Killam AP. Induced abortion: a risk factor for placenta previa. *Am J Obstet Gynecol* 1981;141:769–72.
365. Lopes A, King PA, Duthie SJ, et al. The impact of multiple induced abortions on the outcome of subsequent pregnancy. *Aust N Z J Obstet Gynaecol* 1991;31:41–3.
366. Hendricks MS, Chow YH, Bhagavath B, et al. Previous Caesarean section and abortion as risk factors for developing placenta previa. *J Obstet Gynaecol Res* 1999;25:137–42.
367. Tuzović L, Djelmis J, Ilijić M. Obstetric risk factors associated with placenta previa development: case-control study. *Croat Med J* 2003;44:728–33.
368. Shah PS, Zao J, Knowledge Synthesis Group of Determinants of Preterm/LBW Births. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. *BJOG* 2009;116:1425–42.
369. Swingle HM, Colaizy TT, Zimmerman MB, et al. Abortion and the risk of subsequent preterm birth: a systematic review with meta-analyses. *J Reprod Med* 2009;54:95–108.
370. Ancel PY, Lelong N, Papiernik E, et al. History of induced abortion as a risk factor for preterm birth in European countries: results of the EUROPOP survey. *Hum Reprod* 2004;19:734–40.
371. De Haas I, Harlow BL, Cramer DW, et al. Spontaneous preterm birth: a case-control study. *Am J Obstet Gynecol* 1991;165:1290–6.
372. Freak-Poli R, Chan A, Tucker G, et al. Previous abortion and risk of pre-term birth: a population study. *J Matern Fetal Neonatal Med* 2009;22:1–7.
373. Henriot L, Kaminski M. Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. *BJOG* 2001;108:1036–42.
374. Martius JA, Steck T, Oehler MK, et al. Risk factors associated with preterm (<37 + 0 weeks) and early preterm birth (<32 + 0 weeks): univariate and multivariate analysis of 106 345 singleton births from the

- 1994 statewide perinatal survey of Bavaria. *Eur J Obstet Gynecol Reprod Biol* 1998;80:183–9.
375. Moreau C, Kaminski M, Ancel PY, et al. Previous induced abortions and the risk of very preterm delivery: results of the EPIPAGE study. *BJOG* 2005;112:430–7.
376. Pickering RM, Forbes JF. Risks of preterm delivery and small-for-gestational age infants following abortion: a population study. *Br J Obstet Gynaecol* 1985;92:1106–12.
377. Voigt M, Henrich W, Zygmunt M, et al. Is induced abortion a risk factor in subsequent pregnancy? *J Perinat Med* 2009;37:144–9.
378. Zhou W, Sorensen HT, Olsen J. Induced abortion and subsequent pregnancy duration. *Obstet Gynecol* 1999;94:948–53.
379. Che Y, Zhou W, Gao E, et al. Induced abortion and prematurity in a subsequent pregnancy: a study from Shanghai. *J Obstet Gynaecol* 2001;21:270–3.
380. Mandelson MT, Maden CB, Daling JR. Low birth weight in relation to multiple induced abortions. *Am J Public Health* 1992;82:391–4.
381. Holmlund S, Kauko T, Matomäki J, et al. Induced abortion: impact on a subsequent pregnancy in first-time mothers: a registry-based study. *BMC Pregnancy Childbirth* 2016;16:325.
382. Shachar BZ, Mayo JA, Lyell DJ, et al. Interpregnancy interval after live birth or pregnancy termination and estimated risk of preterm birth: a retrospective cohort study. *BJOG* 2016;123:2009–17.
383. Oliver-Williams C, Fleming M, Monteath K, et al. Changes in association between previous therapeutic abortion and preterm birth in Scotland, 1980 to 2008: a historical cohort study. *PLoS Med* 2013;10:e1001481.
384. Chung CS, Smith RG, Steinhoff PG, et al. Induced abortion and spontaneous fetal loss in subsequent pregnancies. *Am J Public Health* 1982;72:548–54.
385. El-Bastawissi AY, Sorensen TK, Akafomo CK, et al. History of fetal loss and other adverse pregnancy outcomes in relation to subsequent risk of preterm delivery. *Matern Child Health J* 2003;7:53–8.
386. Mandelin M, Karjalainen O. Pregnancy outcome after previous induced abortion. *Ann Chir Gynaecol* 1979;68:147–54.
387. Van der Slikke JW, Treffers PE. Influence of induced abortion on gestational duration in subsequent pregnancies. *Br Med J* 1978;1:270–2.
388. Hogue CJ. Low birth weight subsequent to induced abortion: a historical prospective study of 948 women in Skopje, Yugoslavia. *Am J Obstet Gynecol* 1975;123:675–81.
389. Meirik O, Nygren KG, Bergström R, et al. Outcome of delivery subsequent to induced vacuum-aspiration abortion in parous women. *Am J Epidemiol* 1982;116:415–29.
390. Raatikainen K, Heiskanen N, Heinonen S. Induced abortion: not an independent risk factor for pregnancy outcome, but a challenge for health counseling. *Ann Epidemiol* 2006;16:587–92.
391. Harlap S, Davies AM. Late sequelae of induced abortion: complications and outcome of pregnancy and labor. *Am J Epidemiol* 1975;102:217–24.
392. Lumley J. Very low birth-weight (less than 1,500 g) and previous induced abortion: Victoria 1982–1983. *Aust N Z J Obstet Gynaecol* 1986;26:268–72.
393. Reime B, Schücking BA, Wenzlaff P. Reproductive outcomes in adolescents who had a previous birth or an induced abortion compared to adolescents' first pregnancies. *BMC Pregnancy Childbirth* 2008;8:4.
394. Lahteenmaki P. Postabortal contraception. *Ann Med* 1993;25:185–9.
395. Stoddard A, Eisenberg DL. Controversies in family planning: timing of ovulation after abortion and the conundrum of postabortion intrauterine device insertion. *Contraception* 2011;84:119–21.
396. Schreiber CA, Sober S, Ratcliffe S, et al. Ovulation resumption after medical abortion with mifepristone and misoprostol. *Contraception* 2011;84:230–3.
397. Boyd EF, Holmstrom EG. Ovulation following therapeutic abortion. *Am J Obstet Gynecol* 1972;113:469–73.
398. Langston AM, Joslin-Roher SL, Westhoff CL. Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice. *Contraception* 2014;89:103–8.
399. Rose SB, Lawton BA. Impact of long-acting reversible contraception on return for repeat abortion. *Am J Obstet Gynecol* 2012;206:37, e1–6.
400. Okusanya BO, Oduwole O, Effa EE. Immediate postabortal insertion of intrauterine devices. *Cochrane Database Syst Rev* 2014;(7):CD001777.
401. Black A, Guilbert E, Costescu D, et al. Canadian Contraception Consensus (part 3 of 4): chapter 7 – intrauterine contraception. *J Obstet Gynaecol Can* 2016;38:182–222.
402. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65:1–103.
403. World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015. Available at: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1. Accessed on September 20, 2017.
404. Grimes DA, Lopez LM, Schulz KF, et al. Immediate postabortal insertion of intrauterine devices. *Cochrane Database Syst Rev* 2010;(6):CD001777.
405. Steenland MW, Tepper NK, Curtis KM, et al. Intrauterine contraceptive insertion postabortion: a systematic review. *Contraception* 2011;84:447–64.
406. Drey EA, Reeves MF, Ogawa DD, et al. Insertion of intrauterine contraceptives immediately following first- and second-trimester abortions. *Contraception* 2009;79:397–402.
407. Fox MC, Oat-Judge J, Severson K, et al. Immediate placement of intrauterine devices after first and second trimester pregnancy termination. *Contraception* 2011;83:34–40.
408. Pohjoranta E, Mentula M, Gissler M, et al. Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: first-year results of a randomized controlled trial. *Hum Reprod* 2015;30:2539–46.
409. Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. *Cochrane Database Syst Rev* 2009;(3):CD007373.
410. Rose SB, Garrett SM, Stanley J. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond. *Contraception* 2015;92:17–25.
411. Goodman S, Hendlish SK, Benedict C, et al. Increasing intrauterine contraception use by reducing barriers to post-abortion and interval insertion. *Contraception* 2008;78:136–42.
412. Lähteenmäki P, Rasi V, Luukkainen T, et al. Coagulation factors in women using oral contraceptives or intrauterine contraceptive devices immediately after abortion. *Am J Obstet Gynecol* 1981;141:175–9.
413. Gaffield ME, Kapp N, Ravi A. Use of combined oral contraceptives post abortion. *Contraception* 2009;80:355–62.

414. Fine PM, Tryggestad J, Meyers NJ, et al. Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. *Contraception* 2007;75:367–71.
415. Steinauer JE, Sokoloff A, Roberts EM, et al. Immediate versus delayed initiation of the contraceptive patch after abortion: a randomized trial. *Contraception* 2014;89:42–7.
416. Micks E, Prager S, Plan A. postabortion contraception. *Clin Obstet Gynecol* 2014;57:751–62.
417. Gemzell-Danielsson K, Kopp KH, Faundes A. Contraception following abortion and the treatment of incomplete abortion. *Int J Gynaecol Obstet* 2014;126(Suppl 1):S52–5.
418. Rodriguez MI, Curtis KM, Gaffield ML, et al. Advance supply of emergency contraception: a systematic review. *Contraception* 2013;87:590–601.
419. Roe AH, Bartz D. Contraception after surgical and medical abortion: a review. *Obstet Gynecol Surv* 2017;72:487–93.
420. Cheng MC, Rochat RW. The safety of combined abortion-sterilization procedure. *Am J Obstet Gynecol* 1977;129:548–52.
421. Cheng MC, Chew SC, Cheong J, et al. Safety of postabortion sterilisation compared with interval sterilisation: a controlled study. *Lancet* 1979;2:682–5.
422. Akhter HH, Flock ML, Rubin GL. Safety of abortion and tubal sterilization performed separately versus concurrently. *Am J Obstet Gynecol* 1985;152:619–23.